University of New Orleans

ScholarWorks@UNO
University of New Orleans Theses and
Dissertations

Dissertations and Theses

8-8-2007

Synthesis and Biological Evaluation of Novel GBR 12909 Tropane
and Azetidine Hybrid Analogues
Shaine A. Cararas
University of New Orleans

Follow this and additional works at: https://scholarworks.uno.edu/td

Recommended Citation
Cararas, Shaine A., "Synthesis and Biological Evaluation of Novel GBR 12909 Tropane and Azetidine
Hybrid Analogues" (2007). University of New Orleans Theses and Dissertations. 565.
https://scholarworks.uno.edu/td/565

This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO
with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an
authorized administrator of ScholarWorks@UNO. For more information, please contact scholarworks@uno.edu.

Synthesis and Biological Evaluation of Novel GBR 12909 Tropane and Azetidine
Hybrid Analogues

A Dissertation

Submitted to the Graduate Faculty of the
University of New Orleans
in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
in
Chemistry

by
Shaine A. Cararas
B.S., University of New Orleans, 1999
August 2007

Dedicated to:
Polly

ii

Acknowledgements
The author wishes to thank his advisor, Dr. Mark L. Trudell, for his patience, guidance,
support and friendship over the years. The author is grateful and honored to have been able to
work for Dr. Trudell throughout the years. The author wishes to thank his research advisory
committee, Professor Branko S. Jursic, Professor Matthew A. Tarr, Professor Guijun Wang and
Professor John B. Wiley.
The author appreciates Dr. Sari Izenwasser and Dean Wade for doing the biological
assays and for their patience and support in teaching him how to do the biological assays,
behavioral studies and neurochemistry studies. It was a privilege to work in the laboratories at
the Miller School of Medicine, Miami, Florida. He is grateful to the National Institute of Health
(Ruth L. Kirschstein National Research Service Award DA14155-3) for financial support.

iii

Table of Contents
List of Figures................................................................................................................ vi
List of Tables ................................................................................................................ vii
Abstract ....................................................................................................................... viii
Introduction .................................................................................................................... 1
Cocaine ...................................................................................................................... 1
Cocaine Mode of Action............................................................................................. 3
Binding Constants ...................................................................................................... 4
GBR 12909 Structure Activity Relationship ............................................................... 4
Rational for Design of Novel GBR-Related Analogues ............................................ 20
Objectives ................................................................................................................ 21
Synthesis of 8-alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]
octane analogues ...................................................................................................... 24
Synthesis of 3-diphenylmethoxyalkyl-8-substituted-azetidine
analogues ................................................................................................................. 26
Construction of Azetidine Ring Systems .................................................................. 29
Results and Discussion.................................................................................................. 34
GBR 12909-Tropane Hybrids: Synthesis of 8-Alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane Analogues..................................................... 34
Resolution of 8-Alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane Analogues..................................................... 38
Attempted Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues ................................................................... 47
iv

Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues ................ 49
Biology: Dopamine, Serotonin and Norepinephrine Transporter Affinity ................. 59
GBR 12909-Tropane Hybrids-Synthesis of 8-Alkyl-3-diarylmethoxyethylidenyl-8-aza-bicyclo[3.2.1]octane Analogues ................................................... 60
Conclusions .................................................................................................................. 65
Experimental................................................................................................................. 66
References .................................................................................................................... 96
Vita............................................................................................................................. 105

v

List of Figures
Figure 1. Target GBR 12909 Hybrid Analogues........................................................... 23
Figure 2. Target Azetidine Analogues .......................................................................... 24
Figure 3. Conformation of 3-Alkylidenylazetidine 29 and 3-Alkylazetidine 30............. 27
Figure 4. Important Azetidine Derivatives.................................................................... 30
Figure 5. Plane of Symmetry Through the Tropane Skeleton........................................ 38
Figure 6. Attempted Nitrogen Atom Debenzylation...................................................... 45
Figure 7. Steric Interference from Tropane Ring and Substituents ................................ 46
Figure 8. Azetidine Ketal Formation ............................................................................ 52
Figure 9. Side Reaction with Triphenylphosphine ........................................................ 57

vi

List of Tables
Table 1. Inhibition of [3H] Win 35,428, [3H] Citalopram and [3H] Nisoxetine............... 62
Table 2. clogP values of N-4-Substituted Benzyl Analogues 28g-i................................. 64

vii

Abstract
The high affinity, selective dopamine transporter ligand GBR 12909 has served as a
template for the design of two novel classes of dopamine transporter ligands. A series of 3-[2(diarylmethoxyethyidenyl)]-N-substituted tropane derivatives were synthesized and the binding
affinities of these compounds were determined at the dopamine (DAT), serotonin (SERT) and
norepinephrine (NET) transporters in rat brain tissue preparations. The tropane derivatives were
found to exhibit more potent affinity and selectivity for DAT than GBR 12909. From the SAR
of the tropane analogues and GBR 12909, a novel series of 3-[2-(diarylmethoxyethylidenyl)]-Nsubstituted azetidine derivatives has been developed.

Keywords: Dopamine, serotonin, norepinephrine, tropane, GBR 12909, azetidine
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Introduction
Cocaine
Cocaine (1) is a powerful stimulant that is isolated from the leaves of Erythroxylum coca,
a plant found in South America.1 The psychostimulant affects the central nervous system causing
euphoria, an increase in heart rate and an increase in locomotor activity.2 Cocaine is known to be
highly addictive and a life-threatening problem.
Although cocaine inhibits the serotonin, norepinephrine, and dopamine reuptake systems,
it is believed that cocaine binding to the dopamine transporter is responsible for the stimulant
and reinforcing effects of the drug.3 Cocaine is believed to block the reuptake of dopamine (2) at
the dopamine transporter. This leads to an increased concentration of dopamine in the synapse
and increased occupation of postsynaptic receptors by dopamine that causes the increased
stimulation and up-regulation of dopamine receptors.3, 4
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Dopamine (2)

Cocaine is a psycho stimulant that has historical significance. Its history includes
enhancing the lifestyle of the ancient Incan empire, an anesthetic for optical surgery, prescribed
by Sigmund Freud for depressed patients and finally as the worlds most addictive and exploited
drug. Ancient Incans would chew the leaf of the coca plant, Erythroxylum coca, along with an
alkaline mixture to extract the cocaine from the leaf when traveling on foot and were able to
travel greater distances in less time and with less food. It was known that the effects of the coca
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leaf without the alkali mixture were not produced. Cocaine in the free-base form is known today
as the popular drug, “crack”, or crack-cocaine.5
Sigmund Freud prescribed cocaine to his more depressed patients and eventually Freud
became addicted to cocaine as well.6, 7 Cocaine was demonized as being used by the poor,
uneducated members of society, however, at the beginning of the 1900’s, cocaine was more
popular with the aristocrats and well-to-do people of society because of the high cost of cocaine.
Many became addicted to the drug. Cocaine is the most addictive drug in the world and has been
suggested to be more addictive in adolescence than in adults. 6, 7 Studies have shown that the
addictive properties of cocaine are more pronounced in periadolescent rats than in adult rats. 7
In South America, countries like Peru and Columbia were the major suppliers of cocaine
to the United States and other parts of the world. Cocaine production was, and still is, a way of
life and the sole means of income for many farmers to support their families. Because of the
climate in these countries and the long life of the cocaine-producing plant, cocaine farming is
more economical than some food production.6
In the late 1970’s and early 1980’s, cocaine had grown into a billion dollar industry and
Reagan’s War on Drugs campaign only added fuel to the fire. Drug lords in Columbia, like
Pablo Escobar, started sending as many as 80 airplanes full of cocaine to the United States
everyday with the idea that the Drug Enforcement Agency (DEA) could only catch a few planes
on any given day. Pablo Escobar was the most notorious drug lord in South America making
over a million dollars a day. In the 1980’s it was estimated that children as young as 12 years old
used cocaine. In 2001, approximately 15.9 million Americans aged 12 years or older used illicit
drugs; 1.2 million are current cocaine users.8 The National Drug Control Policy office estimates
that number to be higher than 3.5 million chronic cocaine users.9
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Cocaine Mode of Action
Cocaine binds to the monoamine transporters dopamine (DAT), serotonin (SERT) and
norepinephrine (NET) blocking the reuptake of these neurotransmitters through the monoamine
transporters.10 Cocaine also binds to adrenergic, muscarinic, -receptors and sodium channels.
Specifically, dopamine is normally released into the synapse and reuptake occurs across the
dopamine transporter located on presynaptic nerve terminals.8 Two Na+ ions and one Cl- ion bind
at the transporter to allow for dopamine reuptake and finally the Na+ and Cl- ions cross the
dopamine transporter as well. The mode of action of cocaine and subsequent addictive
properties are caused by cocaine binding to the dopamine transporter and blocking the reuptake
of dopamine in the synapse. Structure-activity relationship (SAR) studies have suggested that
structurally diverse dopamine uptake inhibitors have binding affinities associated to two different
binding sites on the dopamine transporter. 11-14 It was also mentioned by Izenwasser that cocaine
competitively binds to a Na+ ion binding site on the dopamine transporter suggesting cocaine
binding at two binding sites in the nucleus accumbens.15
To be a potential cocaine therapeutic, a high binding affinity for the dopamine
transporter, a long duration of action and slow onset of the drug would be desirable.8 A slow
onset of the drug should not cause the same effects as cocaine which has a fast onset; therefore,
the “rush” is not induced by increasing the amount of dopamine in the synapse by the drug. A
long duration of the drug would allow the drug to stay bound to the dopamine transporter and
eventually be washed away.
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Binding Constants
The concentration of drug needed to bind to the dopamine transporter can be measured
by determining the concentration needed to produce 50% inhibition, (IC50), of a radiolabeled
ligand selective for dopamine transporter binding. When the drug displaces 50% of the
radiolabeled ligand from the dopamine transporter, the concentration is determined as the IC50
value. The binding affinity is expressed as the inhibition constant Ki, which is calculated from
the measured IC50 value by using the equation manifested by Cheng and Prusoff.16 The substrate
concentration, S, is the radio labeled ligand and KM is the Michaelis constant for the substrate
and is determined specifically for each substrate. Since these are inhibition constants, smaller Ki
values correspond to increased potency (affinity) at the transporter.
Ki = IC50/(1 + S/KM)
Selectivity for the dopamine, serotonin and norepinephrine transporters is determined by
the ability of the drug to displace the radio labeled ligands [3H]WIN 35,428, [3H]citalopram, and
[3H]nisoxetine, respectively, from the monoamine transporters.7, 8
GBR 12909 Structure Activity Relationship
The piperazine compound, GBR 12909 (3) synthesized by van der Zee et al., was found
to be a high affinity ligand (Ki = 12 nM) for the dopamine transporter.17 GBR12909 is selective
for the dopamine transporter over the serotonin transporter and is not self-administered in nonhuman primates; 18, 19 however, GBR 12909 also binds to -receptors, which is believed to be the
source of dysphoria observed in humans.20
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Based on the selectivity of GBR 12909 for the dopamine transporter over the serotonin
transporter (SERT/ DAT = 35), GBR 12909 has been identified as a lead compound for the
development of more selective analogues. Substitution around the rings of the benzhydryl
moiety plays a vital role in dopamine transporter binding. Varying the size and shape of the ring
and number of nitrogen atoms in the ring causes a variation in binding affinity. Furthermore,
alkyl substitution on the nitrogen atom distal to the benzhydryl group has an effect on dopamine
transporter binding. The distal and proximal positions are:
proximal
F
O

F

N

N

distal

The benzhydryl moiety plays a vital role in dopamine transporter binding. Monosubstitution at the para-position of the phenyl rings with a halide increases affinity binding.
High-affinity binding is displayed with dihalogen-substitution at the para-position with F > Cl >
Br. Kulkarni et al. suggested that when there is a substituent, especially at the ortho-postion on
the ring, this may interfere with the orientation of the phenyl rings by changing the torsion angle
of the diphenylmethoxy moiety which causes a decrease in dopamine transporter binding
affinity.21 Small halogens at the para- and meta-positions of the diphenylmethoxy moiety can be
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tolerated at the dopamine transporter, but high binding affinity requires 4,4’-difluoro phenyl
substitution.21 Many structure activity relationship studies have shown that while the difluoro
benzhydryl moiety causes an increase in binding affinity at the dopamine transporter, it is the
desfluoro benzhydryl moiety that exhibits the greatest selectivity for the dopamine transporter
over the serotonin transporter.
Many structure-activity relationship studies have shown different binding affinities by
varying the shape and size of the piperizine ring or by incorporating different functional groups
into the piperazine skeleton of GBR 12909.22-24 The piperazine analogue 4 showed dopamine
transporter binding affinity equal to that of GBR 12909.25 Winfield et al.24 incorporated an imide
functionality into the piperazine ring to give 5 which led to a decrease in binding affinity at the
dopamine transporter. The expansion of the piperazine ring showed a limit to the size to which it
can be expanded before the binding affinity starts to decrease. Eight-membered perhydrodiazocine rings 6 showed decreased selectivity and binding affinity for the dopamine transporter
and were the limit to size the ring could be expanded. When the rings were opened (7), binding
affinities increased but were not as potent and selective as GBR 12909.26
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The N-alkyl chain length and substituent seem to enhance the potency and selectivity for
the dopamine transporter if a phenylpropyl moiety is incorporated into the piperazine
analogues.27-30 Changing the substituents at the nitrogen atom of the piperazine analogues greatly
affected dopamine transporter binding. It has also been demonstrated that a hydroxyl moiety
incorporated onto the phenylpropyl moiety at the benzylic position of the GBR 12909 analogue 8
possessed binding affinity for the dopamine transporter.31 The (S)-2-hydroxylated analogue 9 of
GBR 12909 exhibited high binding affinity (DAT Ki = 0.75 nM) and was more selective than
GBR 12909 or the (R)-2-hydroxylated for the dopamine transporter. The (S)-9 analogue also
increased extracellular dopamine levels in rats similar to GBR 12909 and was more potent than
(R)-9.
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N

OH

F

F

8

9

It has been proposed that high affinity dopamine transporter ligands reduce
cocaine-maintained responding in rhesus monkeys.31 During these behavioral studies, the rhesus
monkey pushes a lever that administers a dose of cocaine, causing a positive correlation in
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response to pushing the lever. When the rhesus monkey pushes the lever and the drug that
produces no positive effects, the monkey stops pushing the lever because there is no reward
associated with it. The (S)-9 analogue was found to substitute for cocaine and was more potent
than GBR 12909 and the R isomer. In this series of analogues, the (S)-2-hydroxyl unit was
found to be vital for dopamine transporter binding in vitro and in vivo cocaine maintained
responding.
The bis-4-fluorophenyl substituted GBR 12909 compounds usually have higher binding
affinities, but are less selective for the dopamine transporter than the unsubstituted diphenyl
analogues. Following this trend, the unsubstituted diphenyl 2-hydroxylated analogues of 9
showed high affinity for the dopamine transporter, although not as high as the fluorine
substituted analogues, and the selectivity for the dopamine transporter over the serotonin
transporter was in fact higher than the fluorine substituted analogues. Interestingly, the
unsubstituted (S)-2-hydroxylated analogue was 900-fold more selective for the dopamine
transporter over the serotonin transporter.31
The phenylethyl 2-hydroxylated analogue 10 followed the trend that a phenylpropyl
moiety is needed for more potent and selective dopamine transporter ligands. Following the
trend of the analogues of 9, the S isomer was more selective and more potent for the dopamine
transporter than the R isomer. To increase the selectivity for the dopamine transporter, structureactivity relationship studies have shown that unsubstituted diphenyl rings and a phenylpropyl
chain are needed. The R isomer of 10 incorporates the structure needed for the opposite effect
for selective dopamine transporter binding and is one of the least selective dopamine transporter
ligands (SERT/ DAT = 0.5). This suggests that the 2R-hydroxyl group is another factor causing
the decrease in dopamine transporter selectivity over serotonin transporter selectivity.31
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A series of analogues 11 were synthesized32 that incorporate heteroaryl groups, chain
elongation at N1, derivatization of the heteroatom with chain elongation and substitution of the
aryl ring. When R3 and R2 are hydrogen atoms and an unsubstituted aniline moiety is used, the
binding affinity for the dopamine transporter was equipotent to that of GBR 12909. When the
aniline analogue was changed to a benzyl amine, the binding affinity was equipotent with GBR
12909 but decreased as the number of methylene units was increased.
F
O
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N
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R2
N (CH2)n

X

F

11
Para substitution (R1) with -F, -OMe, -Me and -Cl showed no significant difference in
binding affinity at the dopamine transporter. However, a bulkier and strongly electronwithdrawing 4-NO2 moiety showed a slight decrease in binding affinity. When the bulkier
substituents were incorporated onto the ring, binding affinities were significantly decreased. The
4-N(CH3)2 analogue had an IC50 = 109 that is much lower than GBR 12909 (IC50 = 12 nM) and
may be caused by steric bulk and basicity of the nitrogen. The 4-pyridinyl analogue showed a
decrease in binding affinity (IC50 = 32 nM) for the dopamine transporter which indicates that the
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basicity of the pyridinyl nitrogen may cause some unfavorable interaction with the binding site
of the dopamine transporter.32
Substitution of the 3-amino-2-propanol nitrogen with a methyl moiety showed no
decrease in binding affinity. However, substitution with more electron-withdrawing acetyl and
mesyl moieties elicited less potent binding affinities at the dopamine transporter. When the
hydroxyl group was modified by replacing it with an acetoxy or methoxy moiety, the binding
affinity decreased which suggests that the hydroxyl moiety is important in these compounds for
hydrogen-bonding or hydrophilic interactions at the dopamine transporter.32
As previously mentioned, GBR 12909 possesses two nitrogen atoms in its structure
although two nitrogen atoms are not necessary for binding to the dopamine transporter. Dutta et
al.33 proved which of the two nitrogen atoms was essential for dopamine transporter binding
affinity and selectivity. By replacing the nitrogen atom proximal to the benzhydryl moiety with
a carbon atom in the piperazine analogue, binding affinity for the dopamine transporter increased
more so than by replacing the nitrogen atom distal from the benzhydryl group.
proximal
F
O

F

N

N

distal

The cinnamyl derivative 12 of GBR 12909 demonstrated comparable potency (DAT IC50
= 1.9 nM) as a more rigid analogue of GBR 12909.34 Interestingly, the piperidine analogue 13
showed higher affinity for the dopamine transporter than the piperazine analogue 12 and was
more potent for the dopamine transporter over the serotonin transporter, (SERT/DAT = 104). 28
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When the piperidine analogue 13 was incorporated with an alkyne moiety in place of the
trans double bond, the affinity for the dopamine transporter decreased suggesting that a linear
conformation was not favorable at the transporter. Further, the naphthylmethyl piperidine
derivative 14 showed high affinity for the dopamine transporter (DAT Ki = 0.71 nM) and an
increase in dopamine transporter selectivity over the serotonin transporter (SERT/ DAT = 323).28
This suggests that the piperazine and piperidine analogues are not binding to the dopamine
transporter in the same manner.
F
O

N

F

14
The piperidine analogues of GBR 12909 have been reported to show a preference for a
one-carbon chain length between the nitrogen and the aryl derivative that is usually a benzyl
moiety.28-33 The iodo analogue 15 showed increased binding affinity for the dopamine transporter
(DAT IC50 = 0.96 nM) and increased selectivity over the serotonin transporter (SERT/ DAT =
3041). 29 Interestingly, when the large iodine atom is in place of the naphthyl group, the binding
affinity and selectivity for the dopamine transporter increases. This suggests that in these
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piperidine compounds, a large halide atom at the para-position eliminates the need for such
planar -systems like the naphthyl-substituted analogues. It was also suggested that the large
iodine atom might induce changes in the lipophilic and steric interactions at the dopamine
transporter.29
I
O

N

15
Introduction of a para-ethenyl benzyl 16 moiety or a para-ethynyl benzyl 17 moiety was
tolerated by the dopamine transporter and showed selectivity for the transporter over the
serotonin transporter but were not as potent or selective as the iodo analogue 15. However, the
para-ethenylbenzyl analogue 16 showed greater potency for dopamine uptake inhibition than 15.
It was also noted that in the 4-acetylenic substituted benzyl analogues, if the terminal H-atom
was replaced with a methyl group to give 18, the binding affinity decreased due to increased
steric bulk.29
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Substitution around the benzyl ring of the piperidine analogues exhibited a significant
difference in binding affinity. Typically, para-substitution led to higher affinities at the
dopamine transporter whereas meta- or ortho- substitution decreased in binding affinity at the
dopamine transporter. Electron-withdrawing groups on the N-benzyl ring were also favored for
dopamine binding affinity over electron-donating groups. The desfluoro-piperidine analogues
usually are not as potent as the fluorine substituted benzhydryl analogues, but do demonstrate
better selectivity for the dopamine transporter over the serotonin transporter. It is noteworthy
that the 4-NO2 deslfuoro analogue 19 was highly selective for the dopamine transporter over the
serotonin transporter (SERT/ DAT = 859) and in dopamine uptake inhibition studies (SERT/
DAT = 1310). 30
NO2
O

N

19

13

Many of the piperazine and piperidine analogues demonstrated high binding affinity and
selectivity for the dopamine transporter by incorporating many different functional groups
around the molecule. Hydroxy groups incorporated into the alkyl chains or substitution around
the benzyl moiety has been shown to be important for high affinity binding. Introduction of a
hydroxy group into the piperidine ring served to present compounds that were potent at the
dopamine transporter.34 The racemic cis and trans piperidine analogues 20 proved to be potent
dopamine transporter ligands. However, the resolved trans (+)-R, R analogue (DAT IC50 = 0.46
nM) had a high binding affinity much greater than GBR 12909 and its unhydroxylated parent
piperidine compound and was highly selective for the dopamine transporter over the serotonin
transporter (SERT/ DAT = 7800). The cis analogue was approximately three times less potent
than the racemic trans diastereomer. This illustrates the stereochemical importance of the
hydroxyl moiety in these compounds for binding at the dopamine transporter. Interestingly, the
(+)-R, R analogue had a lower dopamine uptake inhibition than what is normally expected for
such a potent ligand. 25, 34
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In vivo studies for the racemic and resolved trans diastereomer produced substantial
results when compared with cocaine. Cocaine produced maximum locomotor responses at 10
mg/kg within the first ten minutes and tapered off to that of the vehicle within three hours after
the initial injection. It took 56 mg/kg of the racemic mixture to invoke maximum response
between twenty to thirty minutes and continued to invoke a locomotor response for three hours.
The (+)-trans isomer induced a response at 56 mg/kg at twenty minutes but locomotor activity
decreased to that of the vehicle. Interestingly, the locomotor activity for a 30 mg/kg dose of
trans-(+)-20 remained elevated throughout the three-hour duration. Significantly, the (-)-trans
isomer only showed locomotor response at doses of 100 mg/kg within twenty minutes but
decreased almost immediately to that of the vehicle and remained constant throughout the rest of
the three hours. In a cocaine discrimination response test in rats trained to discriminate cocaine,
all three compounds tested produced a response in rats. This indicates that the compounds are
not having a problem crossing the blood-brain barrier to reach the dopamine transporter in the
central nervous system.25, 34
As has been previously reported, replacing the nitrogen atom distal to the benzhydryl moiety
decreases binding affinity at the dopamine transporter.29 A series of tropane-based analogues
have been synthesized that show the same trend in binding as the piperidine analogues
synthesized by Dutta. The fluorine-substituted analogue 21 (X = F) (DAT Ki = 144 nM) was
shown to be more potent than cocaine but was significantly less potent than GBR 12909.35 The
chlorine, methyl and methoxy substituted analogues were shown to have binding affinities
equipotent or less than that of the fluorine substituted analogue. Usually, the fluorine-substituted
analogues of any series of dopamine transporter ligands follow a trend that binding affinities
increase with fluorine-substitution. However, the unsubstituted analogue (X = H) was shown to
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have the highest binding affinity at the dopamine transporter over the substituted analogues in
the series (DAT Ki = 98 nM).35 Interestingly, Bradley et al. reported the binding affinity for 21 to
be equipotent with that observed with the unsubstituted analogue 22a (DAT Ki = 99 nM).36 The
rigidity of the tropane ring system in 21 may cause a conformation suitable for binding at the
dopamine transporter where the difference in which nitrogen is replaced is not a factor for high
binding affinities in the tropane-class of compounds. Therefore, it was shown that a piperazine
ring system was not needed for potent binding at the dopamine transporter and nitrogen
replacement was no longer a factor.
The benzyl analogues 22 demonstrated decreased potency at the dopamine transporter.
Interestingly, the 4, 4’-difluoro analogue of 22b was shown to be the most potent (DAT Ki = 5.7
nM) and most selective dopamine transporter ligand (SERT/ DAT = 251) in the series. The 4,
4’-dichloro analogue 22c was the least selective (SERT/ DAT = 9). These findings run counter
to what is normally expected for GBR-based dopamine transporter ligands and is linked to the
incorporation of the benzyl group.36
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X=H
X=F
X = Cl

The N-methyl 3-derivatives 23 were compared to the benzyl and phenylpropyl
derivatives and were generally less potent than the phenylpropyl analogues 22 and slightly more
potent than the benzyl analogues 21. The desfluoro analogue of 23a was the most selective
(SERT/DAT = 243) analogue for the dopamine transporter over the serotonin transporter than its
difluoro, dichloro or monochloro substituted analogues but the least potent (DAT Ki = 58 nM) of
the series. Usually, the desfluoro analogues show greater selectivity for the dopamine
transporter but tend to have diminished potency at the transporter.36
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X
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X = H, Cl

The phenylpropyl analogues 24 demonstrated high binding affinities for the dopamine
transporter except for the dichloro analogue, which was the least selective of the series (SERT/
DAT = 4). The difluoro analogue was shown to be the most potent in the series (DAT Ki = 7.4
nM) but was not very selective for the dopamine transporter (SERT/ DAT = 24). The difluoro
analogue showed a comparable affinity to that of ethylidene analogues 25 although it was not as
selective for the dopamine transporter.36
The ethylidene analogues 25 were synthesized as racemic compounds and designed to
elucidate the stereochemical limits of the dopamine transporter. Constructing a more rigid
compound proved to enhance the potency and selectivity at the dopamine transporter. The least
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potent (DAT Ki = 48 nM) and least selective (SERT/ DAT = 113) of the series was the N-benzyl
desfluoro benzhydryl analogue. Contrary to previous results, the difluoro substituted N-benzyl
analogue was significantly more potent (DAT Ki = 7.9 nM) but was highly selective for the
dopamine transporter (SERT/ DAT = 281). The N-phenylpropyl desfluoro analogue was more
potent than its N-benzyl congener and was the most selective of the ethylidene analogues (SERT/
DAT = 327). Although less selective for the dopamine transporter than the desfluoro analogue,
the N-phenylpropyl difluoro substituted analogue was slightly more potent (DAT Ki = 3.7 nM)
than the other analogues in the series. The results proved that sp2-hybridization of the C3-carbon
atom increased binding affinity and selectivity for the dopamine transporter.36
During a recent biological study by the NIDA Medication Development Program37, the
-tropane isomers were shown to be more potent than GBR 12909 at the dopamine transporter in
HEK cells expressing cDNA for the human dopamine transporter (HEK-hDAT). Specifically,
the tropane analogue, 8-benzyl-3-bis(4-fluorophenyl) methoxyethyl-8-aza-bicyclo[3.2.1]octane, [ALB-III-141 (22b), Ki = 147 nM]37 exhibited dopamine transporter (HEK-hDAT)
affinity approximately twice that of cocaine. In addition, tropane derivative 25 proved to be
even more potent than the -tropane isomers, [ALB-IV-41 (25), Ki = 39 nM]. The alkylidene
derivative 25 was found to be equipotent with GBR 12909.37
N
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The compounds 22 and 25 differ from GBR 12909 by incorporation of the more rigid
tropane skeleton and one nitrogen atom in the bicyclic system. The similarities of the tropane
analogues to that of GBR 12909 include the N-alkyl chain, the benzhydryl moiety and the tether
between the benzhydryloxy moiety and the parent skeleton. These compounds lack two
nitrogens unlike that of GBR 12909 concluding that the second nitrogen is not necessary for
potent dopamine transporter binding affinity.
Zhang et al.38 synthesized a series of N-methyl alkylidenyl tropane analogues 26 and 27.
These compounds demonstrated comparable results to previous trends of other dopamine
transporter ligands. The 4, 4’-difluoro substituted analogues showed increased binding affinity
for the dopamine transporter and increased dopamine uptake inhibition over the desflouro
analogues. This is consistent with previously reported GBR 12909 analogues. Usually, the
desfluoro analogues show increased selectivity for the dopamine transporter when compared to
the difluoro substituted analogues.
The 4, 4’-difluoro substituted analogue of 26 exhibited high binding affinity for the
dopamine transporter (DAT Ki = 19 nM) and increased selectivity for the dopamine transporter
over the serotonin transporter (SERT/ DAT = 189). The amide analogues 27 showed decreased
binding affinity for the dopamine and serotonin transporters, decreased selectivity for the
dopamine transporter and decreased dopamine uptake inhibition.38
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Rationale for Design of Novel GBR-Related Analogues
GBR 12909 exhibits potency at the dopamine transporter but the piperazine ring allows
for this compound to bind to -receptors in the brain. It is believed that by binding to these
receptors GBR 12909 caused patients to experience dysphoria during human clinical trials and,
therefore, GBR 12909 was abandoned as a potential medication. The tropane ring offers a more
rigid bicyclic skeleton that decreases the flexibility of the molecule and subsequently could lead
to a potential decrease in binding to -receptors in the brain. The structure-activity relationship
studies of Dutta et al. proved that the distal nitrogen atom is the one needed for high affinity
binding to the dopamine transporter.29 Studies have suggested that increased pharmacokinetics
may be due to increased lipophilicity of the analogues.39-41
GBR 12909 has a clogP value of 5.37. If a drug is too lipophilic, it will have difficulty
crossing the blood-brain barrier and get stuck in the lipid bilayer.48 Obviously with a clogP value
of 5.37, GBR 12909 is very lipophilic and would not cross the blood-brain barrier very rapidly.
Cocaine has a clogP value of 3.24 and is able to cross the blood-brain barrier very rapidly and
occupy the dopamine transporter. Crack, the freebase form of cocaine has a very fast onset of
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action and is subject to abuse because it is usually inhaled into the lungs where it can enter the
blood stream rapidly where it is carried to the brain.
Objectives
As mentioned before, GBR 12909 has a high binding affinity and is selective for the
dopamine transporter over the serotonin and norepinephrine transporters and is not selfadministered in non-human primates.18, 19 However, GBR 12909 does bind to -receptors, which
is believed to be the cause of dysphoria in humans.17-20 The goal of this research was to develop
novel GBR 12909 tropane hybrid and azetidine analogues for potent dopamine transporter
ligands as potential therapeutics for cocaine addiction. While utilizing the tropane skeleton,
diminished -receptor activity and increased binding affinity and selectivity at the dopamine
transporter is anticipated. The objective for the design of the azetidine analogues was to design
compounds that were less lipophilic than the GBR 12909 tropane hybrid analogues. The
azetidine compounds would keep the rigidity needed for binding to the dopamine transporter and
would have lipophilicity less than or equal to GBR 12909.
Cocaine binds to the dopamine transporter stereoselectively.38 In addition, Meltzer et al.
found that methylphenidate binds to the dopamine transporter stereospecifically but did not
exhibit addictive properties like that of cocaine.43 It is interesting to note that the 3-analogues of
the tropane-based series of compounds have typically been less potent than their 3-conformers.
This indicates that, like cocaine, there is a stereoselective preference in binding affinity to the
dopamine transporter as well as the other monoamine transporters. In other studies to synthesize
potent dopamine uptake inhibitors, a 3-diphenylmethoxyalkyl moiety of the tropane-based
analogues have displayed low binding affinity for the dopamine transporter. Changing the
stereochemistry and substituents around the tropane ring greatly affects the binding affinity.
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Therefore, it was of interest to synthesize compounds that had a stereochemical
preference for the dopamine transporter. It was envisioned that resolution of the racemic mixture
of the alkyidenyl tropane compounds would enhance the binding affinity and selectivity at the
dopamine transporter. Modifying the N-substitution could also enhance selectivity and potency.
Benztropine and phenyltropane analogues substituted at the 2-position have shown to have high
binding affinity to the dopamine transporter. Benztropine analogues incorporate a diphenlymethoxy moiety that is significantly bulkier and less water soluble than the phenyl moiety of the
3-phenyltropane analogues. Increasing the carbon chain length and steric bulk of the substituent
on the nitrogen led to increased binding affinity to the dopamine transporter as well as increasing
the lipophilicity of the compound.43-49 To this end, a series of GBR-tropane hybrid analogues
(Figure 1) and GBR-related azetidine analogues (Figure 2) were designed to further investigate
the binding motifs of monoamine transporters in the hope of identifying new lead compounds for
development of a cocaine medication.
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Figure 1. Target GBR 12909 Tropane Hybrid Analogues
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Figure 2. Target Azetidine Analogues
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Synthesis of 8-alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane analogues
It was envisaged that the synthesis of these analogues would commence with the
commercially available 3-tropinone (35). In the retrosynthetic analysis (Scheme 1), the
olefination of the protected 3-tropinone would provide a scaffold (34) for incorporating
stereochemistry into the molecule. Subsequent reduction of the conjugated ester 34 from the
olefination would provide the allylic alcohol 33 and further ether synthesis would furnish the
substituted diphenylmethoxyethylidene analogues. Deprotection of the secondary nitrogen atom
would set the stage for the final derivatization to provide the final alkylidene analogues (28).
The 3- tropane analogues 22 and 24 synthesized by Bradley et al.37 were shown to be
fairly potent dopamine transporter selective ligands. However, it was thought that bringing the
stereochemistry at the 3-position into a more rigid planar conformation by incorporation of a
double bond would lead to analogues that were more potent and more selective for the dopamine
transporter. As illustrated in Scheme 2, it was concluded that the alkylidene could be resolved
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into the enantiomeric forms of the molecule. Resolution could be carried out by various
techniques that would set the stage early for further derivatization of the analogues and
preparation of enantiomerically pure ligands.

Scheme 1. Retrosynthesis of Tropane Analogues
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Scheme 2. Retrosynthesis of Resolved Enantiomers
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Synthesis of 3-diphenylmethoxyalkyl-8-substituted-azetidine analogues
As mentioned previously, the rationale for synthesizing the novel azetidine analogues
was to keep the rigidity of the tropane hybrid analogues but decrease the lipophilicity for better
bioavailability. Compared to the tropane hybrid analogue (28Ha) (clogP = 6.29) the azetidine
analogue (29) is significantly less lipophilic (clogP = 5.14) and would be expected to have better
bioavailability. These four-membered nitrogen rings are highly strained molecules and the
stability of these molecules during the synthesis was of great importance. Further, when
subsequent incorporation of a double bond is introduced, the molecule adopts an almost planar
conformation, Figure 3. These semi-planar azetidine analogues could be developed from a novel
synthetic strategy that keeps these highly strained compounds intact throughout the process.
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Figure 3. Conformation of 3-Alkylidenylazetidine 29 and 3-Alkylazetidine 30.
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The synthetic approach for these novel azetidines can be seen in the retrosynthetic
analysis depicted in Scheme 3. The synthesis would commence from the straightforward
reaction of the commercially available starting materials epichlorohydrin and the appropriate
alkylamine (i.e. benzylamine). Further oxidation of the alcohol formed from the ring-closed
product would provide the key 3-azetidinone 37. This would be subjected to HornerWadsworth-Emmons olefination and subsequent reduction to furnish the allylic alcohol 36. To
finish the synthesis and obtain the final product, a straightforward ether synthesis with the
appropriately substituted benzhydryl derivative would provide the target diphenylmethoxyalkylidenyl-N-substituted-azetidine analogues 29.

Scheme 3. Restrosynthesis of Unsaturated Azetidine Analogues
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As illustrated in Scheme 4, the saturated azetidine analogues would be synthesized in
similar fashion to the unsaturated highly strained congeners from the alkylidenyl alcohol 36.
Selective hydrogenation of the double bond of 36 would furnish the saturated azetidine
analogues. This selective hydrogenation is predicted to occur in high yield due to the relief of
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ring strain induced by saturation of the double bond. The saturated azetidine alcohol 38 will be
furnished in a straightforward manner from 36, which is readily obtained from azetidinone 37
(Scheme 3). The alcohol 38 in turn will be subjected to a straightforward ether synthesis with
the appropriately substituted benzhydryl derivative, which will provide the target
diphenylmethoxyalkyl-N-substituted-azetidine analogues 30.

Scheme 4. Retrosynthesis of Saturated Azetidine Analouges
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Construction of Azetidine Ring Systems
The challenge of synthesizing azetidine compounds has been attempted with some success
by various other groups. 50-53 Figure 4 shows several of these azetidine derivatives that have been
recently synthesized. Interestingly, the diphenylmethyl azetidine analogue 39 has been reported
to be very stable when stored in the refrigerator for several weeks.50 The stability is thought to be
derived from the two phenyl moieties delocalizing the electron density from the nitrogen atom as
well as steric interactions. This is believed to stabilize the strained ring system.
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Figure 4. Important Azetidine Derivatives
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The few methods that are available for the synthesis of azetidines are somewhat tedious,
limited in scope and low yielding. Of these methods, the procedure developed by Higgins et
al51seemed to be one of the most versatile and highest yielding (Scheme 5). It was reported that
starting with epichlorohydrin and benzylamine, epoxide ring opening occurred to give aminal 42
in moderate yield after two days at room temperature. Following the ring opening, the azetidinol
43 was formed in a modest yield by heating at reflux for three days. It was reported that the
yield of the azetidinol 43 could be increased by protection of the alcohol as the trimethylsilyl
ether 44. Subsequent treatment of 44 in refluxing petroleum ether after three days furnished the
protected azetidine 45 in 35% yield. The silyl ether 45 could then be deprotected with acid to
give the azetidinol in a greater yield and higher purity.
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Scheme 5. Synthesis of Azetindinol 43
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Reagents: i) rt 2 days, pet ether. ii) reflux 3 days, CH3CN, Et3N. iii) N-(trimethylsilyl)
acetamide, pet. ether, reflux 3 h. iv) aq HCl, 5 min.

An elegant synthesis to obtain the key azetidine 37 was recently reported by De Kimpe et
al.54 The intermediate would set the stage for further reaction to obtain the target azetidine
analogues. As illustrated in Scheme 6, the azetidinone 37 would be unmasked from the
protected ketal 46. The azetidine ring would be formed via a reductive condensation process that
proceeds through imine 47 from reaction of the appropriate aldehyde and the
tribromopropylamine 48.
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Scheme 6. Retrosynthesis of Azetidinone 37
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De Kimpe et al. initiated the synthesis of azetidinone 37 by condensation of readily
available starting material 48 and benzaldehyde at room temperature under basic conditions
(Scheme 7). Magnesium sulfate was used to scavenge the water that is produced and drive the
reaction to completion. After purification, the imine 47 was reduced with sodium borohydride
and subsequent ring-closure insued. Displacement of the bromines via methanolysis in refluxing
methanol produced the protected ketal 46 in 52% yield over 3 steps. This set the stage for
unmasking the ketone by methyl ether cleavage with 10 equivalents of concentrated sulfuric acid
for three hours followed by a basic workup. De Kimpe reported the synthesis to afford the
azetidinone 37 in 63% yield. It was also noted that the azetidinone 37 starts to decompose at
room temperature after eight hours and electron-withdrawing or sterically demanding
substituents on the nitrogen atom stabilize the azetidinone from self-condensation.54
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Scheme 7. Synthesis of Azetidinone 37
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Reagents: i) Et3N, benzaldehyde, MgSO4, CH2Cl2, rt 1h. ii) NaBH4,
MeOH, reflux 14 h. iii) H2SO4, rt, 3h.

Based upon the rational described above and the chemistry outlined, the synthesis of the
target GBR-related compounds—GBR-tropane hybrids (Figure 1) and GBR-related azetidines
(Figure 2) were pursued.
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Results and Discussion
GBR 12909-Tropane Hybrids: Synthesis of 8-Alkyl-3-diarylmethoxyethylidenyl-8azabicyclo[3.2.1]octane Analogues
The synthesis of the 8-alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane
analogues commenced with the protection of the nitrogen atom of 3-tropinone (35). It was
envisaged that the basicity of the nitrogen atom could cause complications with further base
promoted reactions. As such, the carbamate 49 was prepared. Three equivalents of ethyl
chloroformate were used to make the carbamate 49 by refluxing in toluene overnight with 3tropinone under a nitrogen atmosphere. Three equivalents of potassium carbonate were used to
keep the reaction media basic and to help scavenge any excess hydrochloric acid that would be
generated during the reaction. After a standard workup and purification, the product 49 was
obtained in 98% on a multigram scale (Scheme 8). The carbamate 49 was subjected to
Masamune-Roush modification of the Horner-Wadsworth-Emmons reaction.55 Normal
olefination reactions usually undergo Wittig reaction conditions whereby an alkylphosphonate is
treated with a strong base and added to the carbonyl compound. Wittig reagents are usually very
reactive and require low temperatures to produce high yielding reactions. Under MasamuneRoush-Horner-Wadsworth-Emmons conditions, the reactions are much cleaner, can be
performed at room temperature and yield the olefination products in high yields. Trimethylphosphonoacetate was added to a stirred solution of lithium chloride in acetonitrile at room
temperature. The hindered base, 1, 8-diazabicylo[5.4.0]undec-7-ene (DBU), was added to the
stirred solution followed by the carbamate 49 in acetonitrile. It was important to add the
reagents in the proper order starting with lithium chloride coordination with the phosphonate to
increase the acidity of the -proton of the phosphonate and subsequently making the reagent
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more reactive at room temperature. The reaction was allowed to stir at room temperature
overnight under an atmosphere of nitrogen. After a standard workup and column
chromatography, the alkene 34 was produced in 87% yield.

Scheme 8. Synthesis of Tropane Analogues
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Reagents: i) EtOCOCl, K2CO3, toluene, . ii) LiCl, (CH3O)2POCH2CO2CH3, DBU, CH3CN.
iii) LiAlH4, THF, 0o C. iv) (Ph)2CHCl or (4-F-Ph)2CHCl, neat, 145o C.

The reduction of the conjugated ester 34 had to be cautiously reacted with lithium
aluminum hydride to yield the allyl alcohol 33. Lithium aluminum hydride usually adds a
hydride via 1,2-addition to reduce the ester to the alcohol. However, in the presence of a
conjugated ester such as 34, there is a potential for 1,4-addition of hydride to the double bond
producing a mixture of side-products. The conjugated ester was carefully added to a solution of
1.2 equivalents of lithium aluminum hydride at 0° C via syringe over 30 minutes under a
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nitrogen atmosphere. After the addition of the ester was complete, the mixture continued to stir
at 0° C. After monitoring the reaction via TLC, it was determined that the reaction was complete
after two hours. The grey mixture was allowed to continue stirring at 0° C while a 10% KOH
solution was very slowly added via syringe. After the first drop of the 10% KOH solution was
added, the reaction mixture bubbled profusely. After the bubbles subsided, the reaction was
slowly quenched and allowed to warm up to room temperature with stirring over one hour. The
mixture was poured into a separatory funnel and the white solid left in the flask was washed with
diethyl ether. The washings were added to the separatory funnel and phosphate buffer (pH = 7)
was added. After workup and purification, the allylic alcohol 33 was obtained in 89% yield.
The allylic alcohol 33 was then reacted with 1.5 equivalents of either chlorodiphenylmethane or bis(4-fluorophenyl)methylchloride to form the new benzhydryl ether derivative 50.
The ether synthesis was performed neat at 145° C for two hours and no workup was required.
After the reaction cooled to room temperature, it was dissolved in a minimal amount of ethyl
acetate and put directly onto a column for purification. The ether 50 was obtained in 59-66%
yield.
The derivatized ether 50 was subjected to carbamate deprotection with refluxing
hydrazine (Scheme 9). Hydrazine monohydrate was added to the protected ether 50 in ethylene
glycol followed by 26 equivalents of potassium hydroxide. The mixture was stirred and brought
to reflux for three hours. The stability of the ether under such harsh conditions was initially
uncertain, but under these basic conditions the ether remained intact. After cooling to room
temperature, the mixture was poured into a separatory funnel and washed with water. Upon
addition of water, the mixture turned a milky white but returned to a clear yellow solution after
mixing with ether. A standard workup and purification yielded the deprotected derivative 51 in
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60-65% yield. Further derivatization of the nitrogen atom of 51 ensued by reaction with the
appropriate alkylbromide. The reaction was carried out in DMF with 1.1 equivalents of the
corresponding alkylbromide and 2.0 equivalents of potassium carbonate. The reaction was
stirred under a nitrogen atmosphere at 80 °C overnight. The reaction was cooled to room
temperature and a standard workup and purification yielded the various N-alkylated analogues 28
in 45%-94%.

Scheme 9. Synthesis of Tropane Analogues
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Resolution of 8-Alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane Analogues
It was of great interest to determine the structure-activity relationships of the resolved 8alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane analogues. It was envisaged that
one enantiomer would potentially be more potent and more selective at the dopamine transporter
than the racemic mixture or the other enantiomer. Enzymatic and kinetic resolutions were
employed but yielded only starting material. Exhaustive attempts to try to resolve the
enantiomers by way of enzymatic and kinetic resolutions failed to resolve the allylic alcohol 33,
vinylic ester 34, allylic ether 50 and nortropane 51.
The problem with trying to resolve these tropane analogues is the plane of symmetry that
goes through the 8-azabicyclo[3.2.1.]octane ring system (Figure 5). This results in a very small
enantiomeric differentiation. Initial attempts were made to resolve the allylic acetate ester 52 by
enzymatic resolution with (PPL) porcine pancreatic lipase at 40° C to furnish the resolved ester
[]20D = -1.36, c = 1.25 (Scheme 10).56 Only a small amount of starting material was resolved
and this approach was abandoned.

Figure 5. Plane of Symmetry Through the Tropane Skeleton
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Scheme 10. Enzymatic Resolution with PPL
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Derivatization of the vinylic carboxylic acid 53 with a menthol auxillary was attempted
with the hope that the diastereomeric esters 54 could be separated by column chromatography or
HPLC (Scheme 11). Although the reaction to make the diastereomeric esters ensued in high
yield, 85-97%, the mixtures proved inseparable by column chromatography or HPLC.
Derivatization of the allylic alcohol 33 with different menthol or camphor auxillaries was also
attempted. The corresponding carbamates were obtained in 61-76% yield; however, these
diastereomeric esters 55 were found to be inseparable as well (Scheme 12).
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Scheme 11. Carboxylate Ester Derivatization
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Scheme 12. Allylic Carbonate Ester Derivatization
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Another attempt to resolve the enantiomers employed the Sharpless epoxidation of the
allylic alcohol 33. It was envisaged that the Sharpless epoxidation would kinetically epoxidize
one alcohol before the other (Scheme 13) giving the epoxide 56 and the resolved allylic alcohol
33. All the attempts to resolve the alcohol by Sharpless epoxidation failed and only starting
material was recovered.

Scheme 13. Sharpless Epoxidation
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Reagents: i) Ti(OiPr)4, (+)-diethyl-tartrate, t-butyl hydrogen peroxide,
molecular sieves, CH2Cl2, -20o C, overnight.

After all attempts to kinetically resolve the enantiomers failed, it was envisaged that
resolution might be achieved by making a diastereomeric salt. Theoretically, one diasteromeric
salt would crystallize better than the other, leaving the other diastereomeric salt in solution.
Filtering the salt followed by freebasing the single diastereomeric salt would give the resolved
alkylidenyltropane derivatives (Scheme 14). This approach, although potentially tedious since
each final analogue would have to be resolved, did offer the advantage that the enantiomers
could be resolved on a multigram scale without the need for column chromatography. In
addition, the crystalline diastereomeric salt could be used to determine the absolute confirmation
of the alkylidene by X-ray crystallography.

41

Scheme 14. Salt Formation
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Many attempts to resolve any of the N-alkylidenyltropane analogues 28 by making a
diastreomeric salt failed. Many chiral acids were used in attempts to make these salts. These
included (+)-or (-)-mandelic acid and (+)-or (-)-tartaric acid. Finally, the N-benzyl desfluoro
analogue 28a was the only structure that was readily resolved (Scheme 15). The salt of (-)-Ldibenzoyl tartaric acid crystallized as the diastereomeric salt and resolved the tropane derivatives
into the corresponding enantiomers.
The N-benzyl desfluoro analogue 28a was dissolved in dry methanol and allowed to stir at
room temperature. An equivalent of the L-or D-dibenzoyl tartaric acid was dissolved in dry
methanol and added to the reaction flask. After stirring for several minutes at room temperature,
a white precipitate persisted and the solution was allowed to stir at room temperature for an
additional five hours. The precipitate was collected by vacuum filtration and the filtrate was
concentrated under reduced pressure. The residue from the filtrate was freebased with
ammonium hydroxide and extracted with chloroform. The organic layer concentrated and
dissolved in dry methanol and subjected to resolution with the other chiral tartaric acid. The
salts were combined in a flask and freebased with ammonium hydroxide. The freebase of the
resolved analogue was separated from the aqueous layer with chloroform. The organic layer was
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evaporated and optical rotations determined as []20D = -17.5 and []20D = +17.0. The
enantiomers in Scheme 15 are ambiguously drawn for simplicity and do not represent the
absolute stereochemistry of the resolved enantiomers. The absolute stereochemistry will be
determined via X-ray crystallography.

Scheme 15. Resolution of Tropane Analogue 28Ha
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Reagents: i) (-)-dibenzoyl-L-tartaric acid, MeOH, rt. ii) NH4OH.
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(+)-28Ha and (-)-28Ha are drawn for clarity but do not represent
the absolute configurations of the enantiomers.

Now that the alkylidene analogues could be resolved, it was thought that simply cleaving
the ether in refluxing hydrochloric acid would afford the allylic alcohol 48. The alcohol could be
derivatized with bis(4-fluorophenyl)methylchloride to produce the 4-fluoro substituted
benzhydryl moiety (Scheme 16). Debenzylation of the nitrogen could have been carried out with
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a simple hydrogenation using 10% Pd/C; however, the presence of the double bond eliminated
use of that transformation. Other means of debenzylation would have to be found.

Scheme 16. Ether Derivatization
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Reagents: i) HCl, MeOH, . ii) bis(4-fluorophenyl)methylchloride, neat, 145 oC

The resolved N-benzyl desfluoro 28Ha compound was initially refluxed in 6M HCl, but
the compound was not readily soluble in aqueous acid. Dissolving the compound in methanol
followed by refluxing in 6M HCl only produced starting material after a basic workup. Finally,
the resolved analogue 28Ha was dissolved in methanol and refluxed with concentrated
hydrochloric acid overnight. The solution was concentrated under reduced pressure and the
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aqueous solution was chilled on an ice bath. The pH was adjusted to pH = 12 with the slow
addition of ammonium hydroxide and extracted with CH2Cl2 to yield the allylic alcohol 57 in
60% yield. The alcohol (57) was derivatized with the appropriate benzhydryl moiety as
mentioned previously to give 28Fa to set the stage for debenzylation and further derivatization of
the resolved analogues.
Attempts at nitrogen atom demethylation have been achieved with the addition of a
carbamate in the initial nitrogen atom protection of 3-tropinone 35 described herein (Scheme 8).
It was envisaged that debenzylation would work in the same fashion and deprotection would
again produce the nortropane 51 (Figure 6).

Figure 6. Attempted Nitrogen Atom Debenzylation
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The N-benzyl difluoro analogue 28a was subjected to debenzylation with three
equivalents of ethylchloroformate and three equivalents K2CO3 in refluxing toluene overnight.
After a standard workup, the reaction yielded only starting material. A stronger, more reactive
carbamate might be more successful at debenzylation. After a thorough search of the literature,
the very reactive -chloroethylchloroformate, ACE-Cl, was identified as a potential reagent for
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debenzylation of the nitrogen atom. However, after several attempts at room temperature and
under refluxing conditions, only starting material was recovered or total decomposition of the
resolved compound 28Fa occurred.
Although very reactive, ACE-Cl should have been able to debenzylate the nitrogen.
However, there could be some steric interactions that keep the benzylic carbon atom from
nucleophilic attack (Figure 7). Because the benzyl moiety is most likely oriented to the back of
the tropane ring, subsequent nucleophilic attack of chloride to release the carbamate intermediate
is hindered by the phenyl ring and the tropane skeleton. As a result, the reaction cannot proceed
further and leads either to recovery of starting material after workup or decomposition.

Figure 7. Steric Interference from Tropane Ring and Substituents
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Other attempts of debenzylation were investigated. It was thought that by selective
oxidation at the benzyl position with potassium permanganate would install a carbonyl
functionality 58. The subsequent amide would be more reactive to deamidation with hydrazine
in refluxing ethylene glycol.
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The N-benzyl difluoro analogue 28 was subjected to oxidation with three equivalents
KMnO4 overnight at room temperature. After workup, the amide 58 was refluxed with five
equivalents hydrazine monohydrate, 25 equivalents KOH in ethylene glycol for three hours.
However, NMR spectra showed only starting material (+)-28Fa. Attempts to debenzylate the
nitrogen atom were abandoned at this point.
O
N

N

F

F

O

O

58

(+)-28a

F

F

Attempted Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues
The synthesis of the 3-diphenylmethoxyalkyl-8-substituted-azetidine analogues
commenced with the readily available benzylamine and epichlorohydrin (Scheme 17).
Benzylamine was added to a reaction flask and dissolved in water. Epichlorohydrine was added
dropwise at 0 °C and the mixture was allowed to stir at room temperature for 3 hours. After
adjusting the pH = 14, the mixture was subjected to a standard workup and the chlorohydrin 42
was isolated in 90% yield. The chlorohydrin 42 was dissolved in dichloromethane and brought
to reflux for 3 days to generate the azetidine. However, after following the reaction via NMR,
the azetidinol 43 was not being formed.
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Scheme 17. Attempted Synthesis of Azetidinol 43
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Reagents; i) H2O. ii) CH2Cl2, Et3N,  3 days.

Another attempt to close the ring was made by reacting the alcohol 42 with trimethylsilylchloride (Scheme 18). This would protect the alcohol from any potential nucleophilic attack
with the chloride causing unwanted side-products. The alcohol was dissolved in
dichloromethane and two equivalents of triethylamine were added. The mixture was brought to
0 °C and trimethylsilylchloride was added dropwise via syringe. The mixture was allowed to stir
at room temperature for three hours under an atmosphere of nitrogen. After a standard workup
and purification via column chromatography, the silyl ether 44 was isolated in 63% yield.
Refluxing for 48 hours in acetonitrile and triethylamine closed the ring giving the azetidinol
ether 45 in 35% yield. The silyl ether was removed with concentrated hydrochloric acid at room
temperature for five minutes to give the azetidinol 43 in quantitative yield. Many attempts were
made to oxidize the alcohol to the azetidinone 37 with several oxidizing agents including Swern
oxidation conditions and pyridinium dichromate. However, all attempts failed due to the
instability of the azetidinone, workup conditions or purification techniques.
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Scheme 18. Attempted Synthesis of Azetidinone 37
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Reagents: i) H2O, rt, 3 h. ii) TMSCl, Et3N, CH2Cl2, rt, 3 h.
iii) CH3CN, Et3N, , 48 h. iv) aq. HCl, rt, 5 min v)[oxidation]

Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues
As illustrated in Scheme 19, the synthesis of the 3-diphenylmethoxyalkyl-8-substitutedazetidine analogues commenced with the synthesis of the amine 61 from the commercially
available starting materials hexemethylenetetramine 59 and 2, 3-dibromopropene 60. The
reaction is known as the Delepine reaction.56 To a three-neck flask fitted with an addition funnel
and a condenser was added hexamethylentetramine in chloroform. The mixture was stirred using
a Hershberg stirrer at reflux. The alkene 60 was added slowly via the addition funnel over one
hour and the reaction was allowed to reflux an additional three hours. The reaction was then
cooled to room temperature and allowed to stand overnight. The white precipitate was filtered
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via vacuum filtration, collected and allowed to air dry. The product was acidified in ethanol,
water and hydrochloric acid and allowed to stand at room temperature for 24 hours.

Scheme 19. Synthesis of Azetidinone 37
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Reagents: i) CHCl3, . ii) EtOH, 12N HCl. iii) aq. HBr . iv) Br2.
v) benzaldehyde, Et3N, benzene, BF3-Et2O, H2O, DST, . vi) NaBH4,
MeOH, . vii) H2SO4, NaOH.

The ammonium chloride salt was filtered via vacuum filtration and the mother liquor
concentrated to dryness. This was dissolved in water and made basic to pH = 13. After
extracting the aqueous layer with ether, the amine 61 was collected and distilled under reduced
pressure in 81% yield. The amine 61 was dissolved in water and acidified to pH = 1 with 48%
HBr. The amine was protected as the salt to keep it from reacting with itself or the bromine in
the bromination step. Bromine was then added dropwise to the amine in water and allowed to
stir at room temperature overnight. After concentrating the mixture under reduced pressure, the
salt 48 was collected as an off-white solid in 85% yield.
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With the salt 48 in hand, this set the stage for derivatization and subsequent ring closure.
Initially, the condensation of the amine 48 with the prospective aldehyde (i.e. benzaldehyde) was
reacted at room temperature in dichloromethane. The reaction is an equilibrium reaction that
generates water. The addition of magnesium sulfate was used to scavenge the water and drive
the reaction to completion. However, attempts at accomplishing this transformation in any
appreciable yield were unsuccessful even under refluxing conditions.
Because the reaction is an equilibrium reaction generating water, it was thought that
azeotropic distillation with benzene would drive the reaction to completion forming the
condensation product 47. Benzene was added to the amine 48 then it was dissolved in water and
triethylamine followed by the addition of benzaldehyde. Initial reactions involving the
condensation and removal of water were not successful. Therefore, a catalytic amount of
BF3•Et2O was added to promote the reaction by acting as a Lewis acid, which would coordinate
to the aldehyde to make it more reactive. After fitting the reaction flask with a Dean-Stark trap
and condenser, the reaction was refluxed overnight. After cooling the reaction mixture to room
temperature, diethyl ether was added to precipitate the ammonium chloride salt. The salt was
filtered and the filtrate concentrated under reduced pressure to afford the crude imine 47.
Initially, the imine was purified via column chromatography giving 47 in 85-90% yield.
However, it was decided that the instability of the imine under purification conditions might give
lower yields. Therefore, the imine was immediately dissolved in dry MeOH, placed under a
nitrogen atmosphere and cooled to 0 °C. Sodium borohydride was added to the solution portion
wise over one hour. With the addition of the reducing agent, the imine is reduced and
subsequent ring closure of the amine occurs. Several attempts were tried in which the sodium
borohydride was added at room temperature in one addition or in larger portions than previously
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describe, however, these attempts produced lower yields. After the final addition of the reducing
agent, the reaction was allowed to come to room temperature and then refluxed overnight.
During the course of the reaction, there are three transformations occurring: (1) the imine
reduction, (2) the ring closure and (3) the nucleophilic substitution with methanol (Figure 8).
When the azetidine is formed, the ketal protecting group prevents the ring from decomposing or
self-condensation.

Figure 8. Azetidine Ketal Formation
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After all the water was collected and removed, the reaction was cooled to room
temperature. The benzene was removed under reduced pressure and a standard workup ensued.
The crude mixture was subjected to purification via column chromatography furnishing the
azetidine 46 in 41-51% yield over four steps.
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The azetidine was dried under vacuum to remove all traces of water. Initial attempts to
deprotect the azetidine under aqueous conditions failed and only starting material was recovered.
Standard acetal or ketal deprotection is performed in aqueous medium with a catalytic amount of
the acid. The deprotection to aquire the azetidinone 37 was performed in water with a catalytic
amount of concentrated sulfuric acid at room temperature overnight. After adjusting the pH =
12, the aqueous layer was extracted with dichloromethane to yield only starting material.
Treatment again of the ketal with water and 10 equivalents of concentrated sulfuric acid
at room temperature overnight proved unreactive. The acidic solution was then refluxed for
several hours but only starting material was acquired. As a last resort, the ketal was thoroughly
dried under reduced pressure to remove all traces of water. The ketal was put on an ice water
bath to lower the temperature to 0 °C. Concentrated sulfuric acid was added drop wise to the
flask until all 10 equivalents were added. The reaction was allowed to stir at room temperature
and the reaction was followed by NMR spectroscopy. After three hours, total transformation of
the ketal to the azetidinone 37 was complete. The reaction was chilled again on an ice water
bath and the temperature reduced to 0 °C. Saturated NaOH was added slowly to the reaction
until a pH = 12 was reached. The mixture was taken up in water and extracted with
dichloromethane.
The azetidinone 37 is highly unstable at room temperature and starts to decompose.54, 58
Therefore, during the workup of the azetidinone, the solvent was concentrated under reduced
pressure with no heat. Further, because of the instability of the newly formed ketone, column
chromatography could not be used to purify the product. Fortunately, the azetidinone was pure
enough by NMR spectroscopy to be carried forward to the next step as illustrated in Scheme 20.
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Scheme 20. Synthesis of Alcohols 36 and 38
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Reagents: i) LiCl, (CH3O)2POCH2CO2CH3, DBU, CH3CN. ii) LiAlH4, THF.
iii) H2, Pd/C, THF.

Following Masamune-Roush-Horner-Wadsworth-Emmons conditions, LiCl was stirred
in acetonitrile. Trimethylphosphonoacetate was added followed by DBU. When the mixture is
not performed in that order, the product of olefination is achieved in much lower yields.
Following the addition, the azetidinone 37 was added as a solution in acetonitrile straight from
the previous deprotection reaction. The olefination reaction is done under an atmosphere of
nitrogen and in dry acetonitrile. Because the azetidinone from the previous reaction is worked
up in water and is too unstable to leave on a drying pump for an extended amount of time, the
absolute exclusion of water was unavoidable. Nevertheless, the reaction was stirred at room
temperature overnight and the olefination product 62 was isolated after a standard workup and
column chromatography in 55% yield over two steps from the ketal 46.
The conjugated ester 62 was taken up in THF and subjected to reduction to the allylic
alcohol 36 with LiAlH4 or reduced to the saturated ester 63 with 10% Pd/C under a hydrogen
atmosphere. The ester 62 was reduced at 0 °C for two hours and quenched with 10% NaOH.
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After workup, the crude allylic alcohol 36 in 89% was identified via NMR spectroscopy along
with approximately 10% of a saturated side product. Because of the reactivity of the conjugated
ester 62, the reaction proceeds at low temperatures to prevent the formation of any side products.
However, every attempt to reduce the ester to the allylic alcohol was contaminated with 10-20%
of the saturated 1, 4-addition product. Further, attempts to purify the alcohol via column
chromatography decreased the yield significantly. Therefore, after workup, the crude mixture
was used in the next step without any further purification.
The ester 62 was also subjected to hydrogenation with 10% Pd/ C under 1atm H2. The
resulting saturated ester 63 was filtered through a layer of Celite and collected. After
concentrating under reduced pressure, the ester 63 was pure via NMR spectroscopy in 89%. The
saturated ester was subjected to the same reduction conditions as the conjugated ester with
LiAlH4 to afford the saturated alcohol 38 in 89% yield.
The stability of the azetidine ring of the unsaturated analogues was of great importance
when selecting the reaction to make the final product 29 and 30. Several reactions were initially
undertaken at lower temperatures to ensure the stability of the ring. The preparation of the ether
29 was initiated with the allylic alcohol and chlorodiphenylmethane in DMF at room temperature
but was eventually heated to 80 °C overnight (Scheme 21). However, the reaction did not
proceed at this temperature. Usually the reaction is performed at high temperatures (145-160°
C).
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Scheme 21. Synthesis of Azetidine 29
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Another attempt was employed to afford the product formed via Wittig olefination.
Unfortunately, the starting Wittig reagent was not commercially available and had to be prepared
from diphenylmethanol and bromoethanol (Scheme 22). This would then be reacted with
triphenylphophine or a trialkylphosphonate to produce the Wittig reagent. This would in turn be
reacted with the azetidinone to furnish the final product.
Diphenylmethanol was condensed with 2-bromoethanol using a Dean-Stark trap to
furnish the ether 65. However, all attempts to make the phosphine reagent failed because the
affinity of the phosphorous atom for the oxygen atom of the ether produced an unwanted side
reaction instead of the desired phosphine reagent (Figure 9). This route was abandoned and
further investigations of reactions with the allylic alcohol were continued.
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Scheme 22. Retrosynthesis of 29
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Figure 9. Side Reaction with Triphenylphosphine
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To make the reaction more reactive so it would proceed at room temperature,
diphenylmethanol was treated with NaH and reacted with half an equivalent of TsCl. The newly
formed tosylate was added to a mixture of NaH and the allylic alcohol 36 and allowed to stir
overnight. After following the reaction via NMR spectroscopy, it was observed that the reaction
was not proceeding at room temperature. The reaction was slowly heated to 60 °C and the
stability of the azetidine ring was observed via NMR spectroscopy to make sure it was still intact
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at higher temperatures (Scheme 23). The reaction was allowed to react overnight at 60 °C. The
mixture was then cooled to room temperature and quenched with water. After workup, the
product was only obtained in 58% crude yield.

Scheme 23. Attempted Azetidine Synthesis
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Reagents: i) NaH, DMF 60o C, overnight. ii) NaH, TsCl, Me3NHCl,
Et3N, CH3CN.

Because of the low yield produced from the previous procedure, other reaction conditions
were investigated. Following the reduction of the conjugated ester 62, the crude allylic alcohol
36 was dissolved in benzene (Scheme 24). To the solution was added p-toluenesulfonic acid
(PTSA) and diphenylmethanol. The flask was fitted with a Dean-Stark trap and refluxed (80 °C)
overnight. The reaction was concentrated under reduced pressure and following a standard
workup and column chromatography, the product was obtained in 17% yield over two steps.
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Scheme 24. Final Step to Azetidine Analogues
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Biology: Dopamine, Serotonin and Norepinephrine Transporter Affinity of GBR 12909
Tropane Hybrid Analogues
All final target compounds synthesized were tested as the oxalate salts. Binding affinities
for the dopamine, serotonin and norepinephrine transporters were determined by the ability of
the drug to displace the radiolabeled ligands [3H]WIN 35,428 (67, [3H]Citalopram (68), and
[3H]Nisoxetine (69), respectively, from the monoamine transporters found in rat caudateputamen tissue.7, 12, 59
The binding affinities of all compounds listed in Table 1 were initially determined for the
dopamine transporter. The compounds that exhibited dopamine transporter binding affinities
with values Ki < 100 nM were evaluated at the serotonin and norepinephrine transporters to
determine transporter selectivity. Those compounds that exhibited low binding affinity (Ki > 100
nM) at dopamine transporters were typically not evaluated further.
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The racemic analogue 28Ha was fairly potent (DAT Ki = 48 nM, SERT/ DAT = 113) and
selective for the dopamine transporter over the serotonin transporter. However, the resolved
analogues (+)-28Ha and (-)-28Ha varied, as expected, in the ability to displace the tritiated
ligands from the appropriate monoamine transporters.
F
CH3

N

F

O

O

H3CO

NC

[3H]WIN
67

35,428

NHCH3

N

CO2CH3

[3H]Citalopram

[3H]Nisoxetine
69

68

Interestingly, (+)-28Ha was 3-fold more potent and more selective than the racemic
mixture (DAT Ki = 16 nM, SERT/ DAT = 316). Further, (+)-28Ha was 8-fold more potent and
7-fold more selective for the dopamine transporter over the serotonin transporter than its
enantiomer (-)-28Ha (DAT Ki = 134 nM, SERT/ DAT = 46) and it was also equipotent with
GBR 12909 (DAT Ki = 12 nM, SERT/ DAT = 35). The (-)-isomer (-)-28Ha was 3-fold less
potent than the racemic mixture at the dopamine transporter and there was a 2.5-fold decrease in
selectivity for the dopamine transporter over the serotonin transporter. Although the
stereoselectivity of the dopamine transporter of the enantiomeric form of 28Ha was not as
dramatic as that observed for the stereoisomers of cocaine.13, 19 These results further illustrate the
sensitivity of the dopamine transporter to stereochemical differences in ligand topology.
Given the modest difference in binding affinity between the stereoisomers of 28a the
other analogues (28b-i) were tested as the unresolved mixture of racemates. The desfluoro
analogues 28Hb, 28Hc, 28Hd, 28He and 28Hf were found not to be very potent at the dopamine
transporter. The propyl analogue 28Hc (DAT Ki = 245 nM) was equipotent with the ethyl
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analogue 28Hb (DAT Ki = 286 nM). However, the allyl analogue 28He was more potent (DAT
Ki = 143 nM) than the propyl analogue 28Hc. Interstingly, the propargyl analogue 28Hd was
less potent (DAT Ki = 536 nM) than either the propyl analogue 28Hc or the allyl analogue 28He.
The cyclopropymethyl analogue 28Hf (DAT Ki = 169 nM) was also not very potent at the
dopamine transporter.
The 4-fluorophenyl analogues 28Fb-f were tested at the monoamine transporters and
proved to be more potent than the desfluoro analogues 28Hb-f. The ethyl 28Fb (DAT Ki = 40
nM) and propyl 28Fc (DAT Ki = 41 nM) analogues proved to be equipotent but 6- to 7-fold more
potent than their desfluoro analogues. This follows the trend that the 4-fluorophenyl analogues
are more potent than the desfluoro analogues. Further, the allyl analogue 28Fe (DAT Ki = 21
nM) was twice as potent as the ethyl and the propyl analogues 28Fb, c. Interestingly, the
cyclopropylmethyl analogue 28Ff (DAT Ki = 4 nM, SERT/ DAT = 1060) was 3-fold more
potent than GBR 12909 and greater than 30-fold more selective for the dopamine transporter
over the serotonin transporter. This is the most selective dopamine transporter ligand
synthesized to date from these laboratories.
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Table 1. Inhibition of [3H] WIN 35,428, [3H] Citalopram and [3H] Nisoxetine
R

N
X

O

28
X

Cmpda

X

R

GBR12909

DATb

SERTb

(Ki, nM)

(Ki, nM)

NET

SERT/DAT NET/ DAT

(Ki, nM)
35

12 ± 1.9

28Ha

H

Bn

48 ± 5.0

5420 ± 74

1393 ± 147

113

29

28Ha-(+)

H

Bn

16 ± 3.0

5059 ±820

1200 ± 168

316

75

28Ha-(-)

H

Bn

134 ± 6.0

6143 ± 1529

2261 ± 463

46

17

28Fa

F

Bn

7.9 ± 0.5

28Hb

H

Et

286 ± 25

28Fb

F

Et

40 ± 3.0

28Hc

H

Pr

245 ± 20

28Fc

F

Pr

41 ± 7.7

28He

H

CH2CH=CH2

143 ± 15

28Fe

F

CH2CH=CH2

21 ± 2

28Hd

H

CH2CCH

536 ± 49

28Fd

F

CH2CCH

NAc

28Hf

H

CH2Cp

169 ± 44

28Ff

F

CH2Cp

4.0 ± 2.7

4239 ± 225

28Hg

H

4-F-Bn

7.0 ± 1.9

4094 ± 1528

28Fg

F

4-F-Bn

4.9 ± 1.3

281

2220 ± 740

5958 ± 786

3577 ± 117

5463 ± 318

2847 ± 349

3461 ± 314

1145 ± 144

3120 ± 669

3270 ± 127

234

654

d

72

372

168

1244

57

164

68

611

F

4-Cl-Bn

3.9 ± 2.0

656 ± 193

4974 ± 948d

4-CH3-Bn

6.1 ± 1.1

405 ± 98

2132 ± 18
3663

d

4

a) All compounds were tested as the oxalate salts.
b) All values are the mean ± (SEM) of three experiments preformed in triplicate.
c) The compound decomposed and a reliable Ki value could not be obtained.
d) All values are the mean ± (SEM) of three experiments performed in duplicate.
e) All values are the mean ± (SEM) of three experiments.
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149

317

28Fh

F

167

585

2827 ± 222

28Fi

12

d

544 ± 89

746 ± 192

69

2219 ± 543d

7.6 ± 1.0

13 ± 2.0

133

1060

4-Cl-Bn

4-CH3-Bn

89
9

1740 ± 335

H

H

149

2087 ± 335

28Hh

28Hi

8

2430 ± 560

The N-4-substituted-benzyl analogues 28Hh-i and 28Fh-i were tested at the monoamine
transporters and were generally found to be more potent than GBR 12909. The N-(4fluorobenzyl) analogue 28Hg (DAT Ki = 7 nM, SERT/ DAT = 585) was more potent than GBR
12909 and more selective for the dopamine transporter over the serotonin transporter than the
other analogues in this series. The N-(4-fluorobenzyl)-bis(4-fluorophenyl) analogue 28Fg (DAT
Ki = 4.9 nM, SERT/ DAT = 234) was equipotent with its conformer but was about 2-fold less
selective for the dopamine transporter over the serotonin transporter. Further, the N-(4fluorobenzyl) analogues 28Hg and 28Fg were more selective for the dopamine transporter over
the norepinephrine transporter.
The N-(4-chlorobenzyl) analogues 28Hh (DAT Ki = 7.6 nM, SERT/ DAT = 72) and
28Fh (DAT Ki = 3.9 nM, SERT/ DAT = 168) were more potent than GBR 12909 (DAT Ki = 12
nM, SERT/ DAT = 35) and more selective for the dopamine transporter over the serotonin
transporter. However, as the lipophilicity of the substituent on the N-benzyl group (Table 2) was
increased, generally, there was a decrease in selectivity for the dopamine transporter over the
serotonin transporter. This was due to increased serotonin transporter affinity. The N-(4methylbenzyl) analogues 28Hi (DAT Ki = 13 nM, SERT/ DAT = 57) and 28Fi (DAT Ki = 6.1
nM, SERT/ DAT = 68) were the least potent in the series but were equipotent or more potent
than GBR 12909. Further, the N-(4-chlorobenzyl) analogues 28Hh and 28Fh and the N-(4methylbenzyl) analogues 28Hi and 28Fi were more selective for the dopamine transporter over
the norepinephrine transporter. The N-(4-chlorobenzyl) analogue 28Fh (NET/ DAT = 1244) was
the most selective ligand for the dopamine transporter over the norepinephrine transporter in the
series.

63

Table 2. clogP values of N-4-Substituted Benzyl Analogues 28g-i
Cmpd clogP
28Hg

6.44

28Fg

6.72

28Hh

7.01

28Fh

7.29

28Hi

6.79

28Fi

7.08

The tropane hybrid alkylidene analogues are more structurally rigid than GBR 12909.
The bicyclic tropane ring system and the double bond decrease the flexability of the analogues
unlike the piperazine ring system of GBR 12909. However, the similarities to GBR 12909 are
the benzhydryl ether moiety and substitution of the distal nitrogen atom. The tropane hybrid
analogues 28a-i have, generally, been more selective than GBR 12909 for the dopamine
transporter over the serotonin transporter.
Substitution of an N-benzyl or N-alkyl moiety at the nitrogen atom of the tropane hybrid
analogues has demonstrated differences in binding at the dopamine transporter. Overall, the Nbenzyl analogues were more potent than the N-alkyl analogues at the dopamine transporter.
However, the N-cyclopropylmethyl analogue 28Ff was equipotent with several of the N-benzyl
analogues but was the most selective ligand in the series for the dopamine transporter over the
serotonin transporter.
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The structure-activity relationship of the N-4-substitutedbenzyl analogues demonstrated
differences in potency at the dopamine transporter and selectivity for the dopamine transporter
over the serotonin and norepinephrine transporters. The potency increased at the dopamine
transporter as the lipophilicity of the N-para-substituted-benzyl analogue increased. The trend
for increased potency at the dopamine transporter was Cl > F > CH3 > H. The N-4-chlorobenzyl
analogues 28Hh (clogP = 7.01) and 28Fh (clogP = 7.30) were the most lipophilic analogues of
their class. The N-4-chlorobenzyl analogue 28Fh (DAT Ki = 4.0 nM) was the most potent N-4substitutedbenzyl analogue of the series.
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Conclusions
A series of GBR 12909-tropane analogues were synthesized and evaluated at the
dopamine, serotonin and norepinephrine transporters. In general, the tropane hybrid analogues
(28Ha, 28Fb-i) were potent at the dopamine transporter. Several of the GBR 12909-tropane
hybrid analogues proved to be more potent at the dopamine transporter and more selective over
the serotonin transporter than GBR 12909. An enantiomeric resolution of the tropane analogue
28Ha has been developed on a multigram scale. The dopamine transporter binding affinity of
the resolved N-benzyl tropane analogue (+)-28Ha further demonstrated a stereochemical
sensitivity for ligand binding at the dopamine transporter. The resolved enantiomer (+)-28Ha
was equipotent with GBR12909 and more than 3-fold more selective for the dopamine
transporter over the serotonin transporter. Further, the fluoro-substituted analogues are more
potent than the desfluoro analogues. The N-benzyl tropane analogues are more potent than the
N-alkyl tropane analogues. However, the N-cyclopropylmethyl tropane analogue 28Ff (DAT Ki
= 4 nM, SERT/ DAT = 1060) proved to be the most selective dopamine transporter ligand that
has been synthesized in these laboratories to date.
A novel synthesis of several GBR12909 azetidine hybrid analogues was developed. The
rationale for the synthesis of these novel azetidine analogues was to decrease the lipophilicity of
the compound while maintaining the structural rigidity. This will potentially increase the
bioavailability of the compound without decreasing the potency at the dopamine transporter.
These novel GBR 12909 azetidine hybrid analogues are currently being tested at the dopamine,
serotonin and norepinephrine transporters and the biological data will be reported in due course.
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Experimental
General Experimental Methods
All chemicals were purchased from Aldrich Chemical Company and used as received
unless otherwise noted. Anhydrous toluene, dichloromethane (CH2Cl2), methanol (MeOH),
chloroform (CHCl3), tetrahydrofuran (THF) and acetonitrile (CH3CN) were purchased from
Mallinckrodt Baker, Inc. Thin layer chromatography (TLC) 20  20 cm glass plates precoated
with 250 μm silica gel were purchased from Sorbent Technologies and used to monitor reactions
via visualization with short-wave UV light, iodine, potassium permanganate, 2,4 dinitrophenyl
hydrazine or Dragondorff’s reagent. Chromatography was performed over Sorbent Technologies
silica gel 60 angstrom (230-400 mesh). High-pressure hydrogenations were carried out on a Parr
apparatus. Proton and carbon NMR were recorded on a Varian-400 MHz nuclear magnetic
resonance spectrometer at ambient temperature in deuterated chloroform, acetone or water from
Cambridge Isotope Laboratories, Inc. 1H NMR chemical shifts are reported as  values (ppm)
relative to tetramethylsilane. Splitting patterns are designated as: s = singlet, d = doublet, t =
triplet, q = quartet, m = multiplet.

13

C NMR chemical shifts are reported as  values (ppm)

relative to chloroform-d (77.0 ppm). Optical rotations were measured on Autopol III
autopolarimeter at the sodium D line (2 mL sample cell). Melting points (m.p.) were measured
with an Electrothermal  Mel-Temp apparatus and are uncorrected.
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N-Ethoxycarbonyl-8-azabicyclo[3.2.1.]octan-3-one (49)
In a clean, dry 500 mL round-bottom flask was added a stir-bar, 3-tropinone (10.0 g, 72
mmol) and K2CO3 (50 mg). Freshly distilled toluene (90 mL) was added followed by 3
equivalents of ethylchloroformate (21 mL, 220 mmol) via syringe, drop wise. The flask was
fitted with a condenser, nitrogen bubbler and refluxed overnight with stirring. The reaction was
concentrated under vacuum and the brown oil was dissolved in CH2Cl2 (100 mL) and washed
with H2O (100 mL). The layers were separated in a separatory funnel and the aqueous layer
extracted with CH2Cl2 (3  50 mL). The organics were combined and dried over Na2SO4, filtered
and concentrated under vacuum. The residue was purified by column chromatography (SiO2,
EtOAc/ hexane, 1:3) to produce 13.1 g, 92% of a light yellow oil. 1H NMR (400 MHz CDCl3) 
4.51 (bs, 2H), 4.16 (q, J = 7.2 Hz, 2H), 2.63 (bs, 2H), 2.31 (dd, J = 17.4, 1.6 Hz, 2H), 2.07-2.03
(m, 2H), 1.65 (d, J = 7.6 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (400 MHz CDCl3)  208.3,
154.1, 61.6, 53.2, 49.1, 29.5(2), 28.8(2), 14.9.63
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N-Ethoxycarbonyl-3-methoxycarboethylidenyl-8-azabicyclo[3.2.1.]octane (34)
To a clean, dry 500 mL round-bottom flask was added 1.2 equivalents (3.4 g, 80 mmol)
LiCl and a stir bar and sealed under a nitrogen balloon. Acetonitrile (180 mL) was added
followed by 1.2 equivalents of trimethylphosphonoacetate (6.04 mL, 37 mmol). The mixture
was allowed to stir at room temperature for 30 minutes to dissolve the LiCl. DBU (4.60 mL, 31
mmol) was added via syringe, drop wise, over 10 minutes. The protected tropinone 49 (13.1 g,
66 mmol) was dissolved in CH3CN (60 mL) and syringed into the flask. The mixture was all
allowed to stir at room temperature overnight under N2. The reaction was concentrated under
reduced pressure and the light brown oil was dissolved in CH2Cl2 (100 mL) and washed with
H2O (50 mL). The layers were separated in a separatory funnel and the aqeuous layer was
extracted with CH2Cl2 (3  50 mL). The organics were combined and dried over Na2SO4, filtered
and concentrated under vacuum. The residue was purified by column chromatography (SiO2,
EtOAc/ hexane, 1:4) to produce 14.5 g, 87% of a light yellow oil. 1H NMR:  5.79 (s, 1H), 4.39
(brs, 2H), 4.19 (t, J = 6.8 Hz, 2H), 3.69 (s, 3H), 2.69 (brs, 1H), 2.36 (brs, 1H), 2.12 (d, J = 14.4
Hz, 1H), 1.94 (s, 2H), 1.59 (d, J = 7.2 Hz, 2H), 1.28 (t, J = 6.8 Hz, 4H).

13

C NMR:  165.6,

155.2, 153.2, 118.2, 60.4, 53.6, 53.4, 50.3, 42.1, 35.5, 27.9(2), 14.2. Anal. Calc. for C13H19NO4:
C, 61.64; H, 7.56; N, 5.53. Found: C, 61.46; H, 7.66; N, 5.48. NMR data is comparable to
reference 64.
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N-Ethoxycarbonyl-3-hydroxymethylethylidenyl-8-azabicyclo[3.2.1.]octane (33)
Lithium aluminum hydride (1.2 equivalents, 870 mg, 23 mmol) and a stir bar were added
to a clean, dry 250 mL round-bottom flask and sealed under a nitrogen balloon. THF (35 mL)
was added via syringe and the solution brought to 0°C in an ice-water bath. The ester (3.85 g, 15
mmol) was dissolved in THF (15 mL) and added drop wise over 20 minutes via syringe. The
reaction was stirred at 0 °C for 1.5 hours and quenched by the slow addition of 10% KOH (11
mL). Stirring was continued for an additional hour and the reaction mixture was decanted into a
separatory funnel. The white solid was washed with diethyl ether (4  30 mL) and the organics
added to the seperatory funnel. The organics were washed with phosphate buffer (75 mL) and
the buffer extracted with diethyl ether (4  30 mL). The organics were dried over Na2SO4,
filtered and concentrated under reduced pressure. The resulting alcohol was purified by column
chromatography (SiO2, EtOAc/ hexane, 1:1) to yield 3.0 g, 89% of a light yellow oil. 1H NMR:
 5.58 (m, 1H), 4.32 (s, 2H), 4.16 (m, 4H), 2.53 (d, J = 13.6 Hz, 2H), 2.41(d, J = 14 Hz, 2H),
2.23 (d, J = 14.4 Hz, 2H), 2.03 (d, J = 13.6 Hz, 2H), 1.89 (m, 3H), 1.61 (t, J = 7.6 Hz, 2H), 1.52
(t, J = 7.6 Hz, 2H).

13

C NMR:  153.7, 134.4, 127.7, 60.7, 57.7, 53.6, 41.6, 34.5(2), 27.8(2),

14.3. Anal. Calc. for C12H19NO3: C, 63.97; H, 8.50; N, 6.22. Found: C, 63.76; H, 8.61; N, 6.43.
NMR data is comparable to reference 64.
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3-(2-Diarylmethoxy-ethylidene)- N-ethoxycarbonyl-8-azabicyclo[3.2.1]octane (50a)
In a clean, dry 10 mL round-bottom flask was added the alcohol (1.1 g, 5 mmol), bis-4fluorophenylmethylchloride or chlorodiphenylmethane (1.5 equivalents, 1.30 mL, 7 mmol) and a
stir bar. This was heated neat to 145 °C for 2 hours under N2. The reaction was cooled to room
temperature, dissolved in pure ethyl acetate and purified immediately by column
chromatography (60% w/w SiO2, EtOAc/ hexane, 1:4) to afford 1.26g, 66% of 50a as a clear
light yellow oil. 1H NMR:  7.3-7.22 (m, 10H), 5.63-5.61 (M, 1H), 5.39 (s, 1H), 4.36-4.20 (m,
2H), 4.18-4.10 (m, 2H), 4.04-3.98 (m, 2H), 2.55-2.45 (m, 1H) 2.27-2.07 (m, 1H) 1.95-1.86 (m,
2H), 1.64-1.59 (m, 2H), 1.30-1.21 (m, 3H).
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3-(2-Diarylmethoxy-ethylidene)- N-ethoxycarbonyl-8-azabicyclo[3.2.1]octane (50b)
In a clean, dry 10 mL round-bottom flask was added the alcohol (1.4 g, 6.2 mmol), bis-4fluorophenylmethylchloride or chlorodiphenylmethane (1.5 equivalents, 1.70 mL, 9 mmol) and a
stir bar. This was heated neat to 145 °C for 2 hours under N2. The reaction was cooled to room
temperature, dissolved in pure ethyl acetate and purified immediately by column
chromatography (60% w/w SiO2, EtOAc/ hexane, 1:4) to afford 2.0 g, 75% of 50b as a clear
light yellow oil. 1H NMR:  7.3-7.26 (m, 4H), 7.03-6.98 (m, 4H), 5.63-5.61 (M, 1H), 5.39 (s,
1H), 4.36-4.20 (m, 2H), 4.18-4.10 (m, 2H), 4.04-3.98 (m, 2H), 2.55-2.45 (m, 1H) 2.27-2.07 (m,
1H) 1.95-1.86 (m, 2H), 1.64-1.59 (m, 2H), 1.30-1.21 (m, 3H).
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3-(2-Diarylmethoxy-ethylidene)-8-azabicyclo[3.2.1]octane (51)
In a clean 250 mL round-bottom flask was added ethylene glycol (88 mL), 26 equivalents
KOH (4.42 g, 79 mmol), 5 equivalents NH2NH2• H2O (.75 mL, 15 mmol) and the corresponding
protected tropane (1.26 g, 3 mmol). The reaction was heated to reflux for 3 hours. The reaction
was then cooled to room temperature and poured into a separatory funnel and extracted with
diethyl ether (6  75 mL). The combined ether layers were dried over Na2SO4, filtered and
concentrated under reduced pressure. The resulting oil was purified by column chromatography
(SiO2, CHCl3/MeOH/NH4OH 90:9:1.) to afford the nortropane 51 as a light yellow oil.
51a 615 mg, 60% 1H NMR:  7.36- 7.22 (m, 10H), 5.51-5.48 (M, 1H), 5.40 (s, 1H), 4.05-3.97
(m, 2H), 3.57-3.54 (m, 2H), 2.43-2.40 (d, J = 13.6 Hz, 1H), 2.28-2.25 (d, J = 14.0 Hz, 1H) 2.092.01 (t, J = 14.0 Hz, 2H) 1.84 (bs, 2H), 1.73-1.68 (m, 2H) 1.64-1.59 (m, 1H), 1.51-1.47 (m, 1H).
13

C NMR:  142.1(2), 138.0(4), 128.1(4), 126.8(2), 122.9, 82.3, 64.1, 55.1, 54.7, 43.8, 36.9, 29.1,

28.8(2). Anal. Calc. for C22H25NO•0.25 H2O: C, 81.75; H, 7.93; N, 4.33 Found: C, 81.57; H,
7.86; N, 4.35.64
51b 577 mg, 66% 1H NMR:  7.36- 7.22 (m, 4H), 7.02-6.97 (m, 4H) 5.51-5.48 (m, 1H), 5.40 (s,
1H), 4.05-3.97 (m, 2H), 3.57-3.54 (m, 2H), 2.43-2.40 (d, J = 13.6 Hz, 1H), 2.28-2.25 (d, J = 14.0
Hz, 1H) 2.09-2.01 (t, J = 14.0 Hz, 2H) 1.84 (bs, 2H), 1.73-1.68 (m, 2H) 1.64-1.59 (m, 1H), 1.511.47 (m, 1H). 13C NMR:  158.14(2), 138.3, 138.1, 134.4(4), 128.5(2), 128.3(2), 123.1, 115.0,
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81.2, 69.4, 64.1, 55.2, 54.8, 43.8, 36.9, 29.2. Anal. Calc. for C22H23F2NO•0.50 H2O: C, 72.50; H,
6.63; N, 3.84 Found: C, 72.55; H, 6.50; N, 3.84.64
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General procedure for N-alkylation of secondary amines (28a-i)
In a clean, dry 25 mL round-bottom flask was added 600 mg K2CO3, the nortropane 51
(2 mmol), DMF (15 mL) and the alkyl bromide (2 mmol) and a stir bar. The reaction was heated
to 80 °C (oil bath) overnight under N2. The reaction was cooled to room temperature and added
to a separatory funnel followed by addition of H2O (50 mL). The mixture was extracted with
diethyl ether (4 50 mL) and the combined organic layers were dried over Na2SO4, filtered and
concentrated under reduced pressure. The oil was purified by column chromatography and the
pure free base was converted into the oxalate salt.
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3-(2-Diphenylmethoxy-ethylidene)-8-alkyl-8-azabicyclo[3.2.1]octane (28Ha)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28a as a thick
yellow oil (642 mg, 78%). 1H NMR (400 MHz, CDCl3)  7.04-7.21 (m, 15H), 5.52-5.49 (t, J=8
Hz, 1H), 5.39 (s, 1H), 4.05-3.96 (m, 2H), 3.61 (s, 2H), 3.23-3.20 (d, J=12 Hz, 2H), 2.62-2.59 (d,
J=12 Hz, 1H), 2.24-2.09 (dd, J=14 Hz, 2H), 1.95-1.92 (m, 3H), 1.59-1.54 (t, J=8 Hz, 1H), 1.471.42 (t, J=10 Hz, 1H). Anal. Calc. for C29H31NO•C2H2O4: C 74.58; H 6.66; N 2.81. Found: C
74.62; H 6.71; N 2.79.

N

O

(+)-3-(2-Diphenylmethoxy-ethylidene)-8-benzyl-8-azabicyclo[3.2.1]octane (+)-(28Ha)
To a solution of the racemic 28a (350 mg, 0.85 mmol) in MeOH (10 mL), was added a
solution of dibenzoyl-L-tartaric acid (310 mg, 0.87 mmol) in MeOH (10 mL). This was allowed
to stir at room temperature for 5 hours. A white precipitate formed after approximately 30
minutes. The precipitate was collected by filtration through a Buchner funnel and washed with
MeOH (5 mL). The solid was added to a flask in addition to H2O (20 mL). The chiral salt was
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free-based with NH4OH when a pH=12 was reached. The solution was extracted with CHCl3 (4
 10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under
reduced pressure to produce a clear oil. The freebase was treated with a second equivalent of
dibenzoyl-L-tartaric acid and the recrystallization process was repeated until a constant optical
rotation was obtained. The resolved 28a was obtained as a clear oil, 96 mg, []25D +17.0° (c 1.0,
EtOH).

N

O

(-)-3-(2-Diphenylmethoxy-ethylidene)-8-benzyl-8-azabicyclo[3.2.1]octane (-)-(28Ha)
To a solution of the racemic 28Ha (189 mg, 0.46 mmol) in MeOH (10 mL), was added a
solution of dibenzoyl-D-tartaric acid (166 mg, 0.46 mmol) in MeOH (10 mL). The mixture was
allowed to stir at room temperature for 5 hours. A white precipitate formed after approximately
30 minutes. The precipitate was collected by filtration through a Buchner funnel and washed
with MeOH (5 mL). The solid was added to a flask in addition to H2O (20 mL). The chiral salt
was free-based with NH4OH when a pH=12 was reached. This was extracted with CHCl3 (4  10
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under
reduced pressure to produce a clear oil. The freebase was treated with a second equivalent of
dibenzoyl-D-tartaric acid and the recrystallization process was repeated until a constant optical
rotation was obtained. The resolved 28a was obtained as a clear oil, 64 mg []25D -17.5° (c 1.25,
EtOH).
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3-(2-Diphenylmethoxy-ethylidene)-8-ethyl-8-azabicyclo[3.2.1]octane (28Hb)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hb as a thick
oil (207 mg, 50%). 1H NMR (400 MHz, CDCl3)  7.35-7.22 (m, 10H), 5.53-5.50 (t, J=6.6 Hz,
1H), 5.39 (s, 1H), 4.05-3.94 (m, 2H), 3.36-3.32 (d, J=16 Hz, 2H), 2.66-2.62 (d, J=16 Hz, 1H),
2.57-2.52 (q, J=7 Hz, 2H), 2.28-2.25 (d, J=13.2 Hz, 1H), 2.13-2.10 (d, J=14 Hz, 1H) 1.96-1.93
(d, J=14.4 Hz, 1H), 1.87 (s, 2H), 1.59-1.54 (t, J=9.2 Hz, 1H), 1.46-1.42 (t, J=8.8 Hz, 1H), 1.171.13 (t, J=7.2 Hz, 3H). Anal. Calc. for C24H29NO•C2H2O4: C 70.58; H 7.47; N 3.17. Found: C
70.56; H 7.39; N 3.10.
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-ethyl-8-azabicyclo[3.2.1.]octane (28Fb)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fb as a thick
yellow oil (140 mg, 66%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H),
5.49 (s, 1H), 5.33 (s, 1H), 4.01-3.91 (m, 2H), 3.31-3.28 (d, J=12 Hz, 2H), 2.58-2.47 (m, 3H),
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2.21-2.17 (d, J=16 Hz, 1H), 2.09-2.05 (d, J=16 Hz, 1H), 1.13-1.09 (t, J=8 Hz, 3H). Anal. Calc.
for C24H27F2NO•C2H2O4: C 60.17; H 5.98; N 2.70. Found: C 60.10; H 5.88; N 2.45.

N

O

3-(2-Diphenylmethoxy-ethylidene)-8-propyl-8-azabicyclo[3.2.1]octane (28Hc)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hc as a thick
yellow oil (72 mg, 42%). 1H NMR (400 MHz CDCl3)  7.35-7.22 (m, 10H), 5.54 (s, 1H), 5.39 (s,
1H), 4.05-3.94 (m, 2H), 3.38 (bs, 2H), 2.49 (bs, 2H), 2.16 (d, J=13.2 Hz, 2H), 1.98-1.91 (m, 3H),
1.61 (bs, 5H), 0.95 (t, J=7.4 Hz, 3H). Anal. Calc. for C27H31NO•C2H2O4: C 69.06; H 7.51; N
2.98. Found: C 69.67; H 7.30; N 3.01.

N
F

O

F

3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-propyl-8-azabicyclo[3.2.1.]octane (28Fc)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fc as a thick
yellow oil (64 mg, 68%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H),
5.45 (bs, 1H), 5.35 (s, 1H), 3.98-3.93 (m, 2H), 3.26 (bs, 2H), 2.57-2.54 (d, J=12 Hz, 1H), 2.4078

2.36 (t, J=8 Hz, 2H), 2.16-2.04 (m, 2H), 1.92-1.84 (m, 3H) 1.56-1.50 (m, 3H) 1.36 (s, 1H) 0.930.89 (t, J=7.2 Hz, 3H). Anal. Calc. for C25H29F2NO•C2H2O4: C 62.97; H 6.41; N 2.72. Found:
C 62.91; H 5.89; N 2.72.

N
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3-(2-Diphenylmethoxy-ethylidene)-8-(3-prop-2-ynyl)-8-azabicyclo[3.2.1]octane (28Hd)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hd as a thick
yellow oil (169 mg, 61%).

1

H NMR (400 MHz, CDCl3)  7.35-7.23 (m, 10H), 5.51 (t, J-6.4 Hz,

1H), 5.39 (s, 1H), 4.05-3.93 (m, 2H), 3.41-3.38 (d, J=12 Hz, 2H), 3.22 (s, 2H), 2.59-2.55 (d,
J=16 Hz, 1H), 2.20-2.13 (m, 2H), 1.99-1.96 (d, J=12 Hz, 1H), 1.85 (bs, 2H) 1.59-1.56 (d, J=12
Hz, 2H) 1.46-1.42 (t, J=4.4 Hz, 1H). Anal. Calc. for C25H27NO•C2H2O4: C 68.98; H 6.60; N
2.98. Found: C 68.67; H 6.36; N 2.93.
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-(3-prop-2-ynyl)-8-azabicyclo[3.2.1.]octane
(28Fd)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fd as a thick
yellow oil (130 mg, 63%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H),
5.50 (t, J=8 Hz, 1H), 5.34 (s, 1H), 4.01-3.90 (m, 2H), 3.41 (bs, 2H), 3.20 (s, 2H), 2.59-2.56 (d,
J=14 Hz, 1H), 2.21-2.12 (m, 2H), 1.88-1.86 (m, 1H), 1.56 (s, 2H) 1.43-1.39 (m, 2H). Anal. Calc.
for C25H25F2NO•C2H2O4: C 64.60; H 5.78; N 2.79. Found: C 63.80; H 5.50; N 2.59.

N
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8-Allyl-3-(2-diphenylmethoxy-ethylidene)-8-azabicyclo[3.2.1]octane (28He)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28He as a thick
yellow oil (132 mg, 67%). 1H NMR (400 MHz, CDCl3)  7.35-7.21 (m, 10H), 5.96 (bs, 1H), 5.52
(bs, 1H), 5.39 (s, 1H), 5.21-5.14 (t, J=17.6 Hz, 2H) 4.05-3.93 (m, 2H) 3.32-3.29 (d, J=12 Hz,
2H), 3.12-3.10 (d, J=5.6 Hz, 2H), 2.63 (bs, 1H), 2.24 (bs, 1H), 2.16-2.12 (d, J=14 Hz, 1H), 1.98-
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1.95 (d, J=12 Hz, 1H), 1.86 (bs, 2H), 1.60-1.43 (m, 2H). Anal. Calc. for C25H29NO•C2H2O4: C
68.64; H 6.99; N 2.97. Found: C 68.55; H 6.88; N 2.78.

N
F

O

F

8-Allyl-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane (28Fe)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fe as a thick
yellow oil (158 mg, 66%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H),
5.94 (bs, 1H), 5.48 (bs, 1H), 5.34 (s, 1H), 5.20-5.15 (d, J=17.6 Hz, 2H), 4.01-3.90 (m, 2H), 3.28
(bs, 2H), 3.08 (bs, 2H), 2.56 (bs, 1H), 2.12 (m, 2H), 1.97-1.86 (m, 2H), 1.55 (s, 3H). Anal. Calc.
for C25H27F2NO•C2H2O4: C 64.35; H 6.16; N 2.78. Found: C 64.32; H 6.02; N 2.70.

N

O

3-(2-Diphenylmethoxy-ethylidene)-8-cyclopropylmethyl-8-azabicyclo[3.2.1]octane (28Hf)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hf as a thick
yellow oil (227 mg, 45%). 1H NMR (400 MHz, CDCl3)  7.36-7.23 (m, 10H), 5.48 (t, J=6.8 Hz,
1H), 5.39 (s, 1H), 4.05-3.94 (m, 2H), 3.43-3.39 (d, J=16 Hz, 2H), 2.57-2.54 (d, J=12 Hz, 1H),
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2.34-2.33 (d, J=4 Hz, 2H), 2.20-2.07 (m, 3H), 1.93-1.80 (m, 3H), 1.60-1.37 (m, 1H), 0.94 (m,
1H), 0.52 (m, 2H), 0.12 (m, 2H). Anal. Calc. for C26H31NO•C2H2O4: C 69.12; H 6.99; N 2.88.
Found: C 69.00; H 6.97; N 2.83.
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-cyclopropylmethyl-8azabicyclo[3.2.1.]octane (28Ff)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Ff as a thick
yellow oil (140 mg, 65%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H),
5.46 (bs, 1H), 5.35 (s, 1H), 4.01-3.90 (m, 2H), 3.42 (bs, 2H), 2.56 (bs, 1H), 2.17 (bs, 1H), 2.102.06 (d, J=14.8 Hz, 1H), 1.95-1.91 (d, J=14.4 Hz, 1H), 1.83 (bs, 2H), 1.58 (bs, 2H), 0.52-0.50 (d,
J=7.2 Hz, 2H), 0.11-0.10 (d, J=4 Hz, 2H). Anal. Calc. for C26H29F2NO•C2H2O4: C 65.00; H
6.40; N 2.70. Found: C 63.42; H 6.07; N 2.50.
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3-(2-Diphenylmethoxy-ethylidene)-8-(4-fluorobenzyl)-8-azabicyclo[3.2.1]octane (28Hg)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hg as a thick
yellow oil (77 mg, 67%). 1H NMR (400 MHz, CDCl3)  7.38-7.21 (m, 12H) 7.04-6.97 (m, 2H)
5.53-5.50 (t, J=6.4 Hz, 1H) 5.39 (s, 1H) 4.04-3.94 (m, 2H) 3.58 (s, 2H) 3.22 (s, 2H) 2.63-2.60 (d,
J=13.2 Hz, 1H) 2.25-2.22 (d, J=14 Hz, 1H) 2.14-2.10 (d, J=14 Hz, 1H) 1.92 (bs, 3H) 1.60-1.53
(m, 2H). Anal. Calc. for C29H30FNO•C2H2O4: C 71.94; H 6.23; N 3.67. Found: C 66.30; H 5.98;
N 2.44.
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8-(4-Fluorobenzyl)-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane
(28Fg)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fg as a thick
yellow oil (73 mg, 87%). 1H NMR (400 MHz, CDCl3)  7.37-7.25 (m, 6H) 7.06-6.98 (m, 6H)
5.50-5.47 (t, J=6.8 Hz, 1H) 5.35 (s, 1H) 4.01-3.92 (m, 2H) 3.56 (s, 2H) 3.21-3.20 (d, J=4 Hz,
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2H) 2.60-2.57 (d, J=13.6 Hz, 1H) 2.19-1.90 (m, 5H) 1.56 (t, J=10 Hz, 1H) 1.42 (t, J=10 Hz, 1H).
Anal. Calc. for C29H28F3NO•C2H2O4: C 67.26; H 5.46; N 2.53. Found: C 66.44; H 5.45; N
2.56.

Cl

N

O

3-(2-Diphenylmethoxy-ethylidene)-8-(4-chlorobenzyl)-8-azabicyclo[3.2.1]octane (28Hh)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hh as a thick
yellow oil (95 mg, 93%). 1H NMR (400 MHz, CDCl3)  7.39-7.21 (m, 14H) 5.51 (bs, 1H) 5.38
(s, 1H) 4.01-3.97 (m, 2H) 3.59-3.55 (d, J=16 Hz, 2H) 3.18-3.16 (d, J=6.8 Hz, 2H) 2.58-2.55 (d,
J=12 Hz, 1H) 2.17-2.09 (m, 2H) 1.89 (bs, 3H) 1.58-1.44 (m, 2H). Anal. Calc. for
C32H30ClNO•C2H2O4: C 69.72; H 6.04; N 2.62. Found: C 66.30; H 5.98; N 2.44.
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F

O
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8-(4-Chlorobenzyl)-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane
(28Fh)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fh as a thick
yellow oil (56 mg, 74%). 1H NMR (400 MHz, CDCl3)  7.35-7.23 (m, 8H) 7.04-6.97 (m, 4H)
5.48 (t, J=6.8 Hz, 1H) 5.35 (s, 1H) 4.01-3.91 (m, 2H) 3.56 (s, 2H) 3.19 (bs, 2H) 2.60-2.56 (d,
J=14.4 Hz, 1H) 2.22-2.19 (d, J=14 Hz, 1H) 2.11-2.08 (d, J=14 Hz, 1H) 1.96-1.86 (m, 3H) 1.56 (t,
J=9 Hz, 1H) 1.42 (t, J=8.8 Hz, 1H). Anal. Calc. for C29H28F2ClNO•C2H2O4: C 65.32; H 5.30; N
2.46. Found: C 63.74; H 5.26; N 2.63.

H3C

N

O

3-(2-Diphenylmethoxy-ethylidene)-8-(4-methylbenzyl)-8-aza-bicyclo[3.2.1]octane (28Hi)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hi as a thick
yellow oil (74 mg, 60%). 1H NMR (400 MHz, CDCl3)  7.39-7.11 (m, 14H) 5.51-5.48 (t, J=6.4
Hz, 1H) 5.39 (s, 1H) 4.04-3.97 (m, 2H) 3.56 (s, 2H) 3.22-3.19 (d, J=17.6 Hz, 2H) 2.61-2.57 (d,
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J=13.6 Hz, 1H) 2.33 (s, 3H) 2.23-2.19 (d, J=14 Hz, 1H) 2.11-2.08 (d, J=14.4 Hz, 1H) 1.93 (bs,
3H) 1.57-1.43 (m, 2H). Anal. Calc. for C30H33NO•C2H2O4: C 74.83; H 6.87; N 2.73. Found: C
66.30; H 5.98; N 2.44.

H3C

N
F

O

F

3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-(4-methylbenzyl)-8-azabicyclo[3.2.1.]octane
(28Fi)
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fi as a thick
yellow oil (153 mg, 85%). 1H NMR (400 MHz, CDCl3)  7.21-7.16 (m, 4H) 7.06-7.04 (d, J=8
Hz, 4H) 6.94-6.90 (m, 4H) 5.41-5.39 (t, J=8 Hz, 1H) 5.27 (s, 1H) 3.90-3.86 (m, 2H) 3.49 (s, 2H)
3.16-3.13 (m, 2H) 2.54-2.50 (d, J=16 Hz, 1H) 2.26 (s, 3H) 2.16-2.12 (d, J=14 Hz, 1H) 2.02-1.99
(d, J=14 Hz, 1H) 1.86-1.83 (m, 3H) 1.50-1.44 (t, J=8 Hz, 1H) 1.35-1.31 (t, J=8 Hz, 1H). Anal.
Calc. for C30H31F2NO•C2H2O4•H2O: C 67.71; H 6.22; N 2.47. Found: C 66.30; H 5.98; N 2.44.
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Br
NH2

2-Bromopropenamine (61)
In a 1L 3-neck round bottom flask was added 2 equivalents of hexamethylenetetramine
(126 g, 0.90 mol), CHCl3 (800 mL) and fitted with a Hershberg stirrer. The mixture was brought
to reflux with stirring while adding via an addition funnel 2, 3-dibromopropene, 80% (100 g,
0.40 mol) over one hour. The mixture was refluxed an additional 3 hours then cooled to room
temperature overnight without stirring. The mixture was cooled in an ice bath and the salt
filtered via vacuum filtration. The salt was allowed to air-dry overnight.
The salt was added to EtOH (2 L), 12N HCl (480 mL) and H2O (400 mL). This was
allowed to stir one hour then let stand at room temperature for 24 hours. The salt was removed
by vacuum filtration and the filtrate concentrated to approximately 600 mL. The filtrate was
filtered again and concentrated to dryness. The solid residue was dissolved in H2O (300 mL) and
the pH adjusted to pH = 13 with 6N NaOH (200 mL). The aqueous mixture was extracted with
diethyl ether (3  100 mL). The organic layer was dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was distilled under reduced pressure to afford 61 as an offwhite solid (44g, 81%), which was immediately utilized in the next step. 1H NMR (400 MHz,
CDCl3)  5.78 (s, 1H) 5.48 (s, 1H) 3.48 (s, 2H) 1.60 (bs, 2H).65
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Br

Br

NH2 HBr

2, 3-Tribromopropylamine•HBr (48)
The amine from the previous step was dissolved in H2O (70 mL) and brought to 0° C on
an ice bath. HBr (48% solution, 40.5 mL, 0.36 mol) was added slowly with stirring followed by
slow addition of Br2 (25 mL, 0.49 mol). The mixture was allowed to stir at room temperature for
24 hours. The mixture was then concentrated under reduced pressure to afford 48 as an orangewhite solid (104g, 85%). mp 196°-198° C [lit.60 196-198° C]. 1H NMR (400 MHz, D2O)  4.35
(s, 2H) 3.82 (s, 2H). Anal. Calc. for C3H6NBr3•HBr: C 9.56; H 1.87; N 3.72. Found: C 9.66; H
1.81; N 3.70. NMR data is comparable to ref. 60.

MeO

OMe
N

1-Benzyl-3-dimethoxyazetidine (46)
In a 250 mL round bottom flask were added the amine (4.02g, .011 mol), benzaldehyde
(1.2 mL, .011 mol), BF3•Et2O (3 drops), triethylamine (3 mL, .022 mol), H2O (10 mL) and
benzene (100 mL). This was fitted with a Dean-Stark trap and refluxed overnight. The mixture
was cooled to room temperature and diethyl ether (100 mL) was added. The triethylammonium
salts were filtered and the solvent evaporated under reduced pressure. The residue was dissolved
in dry MeOH (50 mL) and flushed with N2. The mixture was cooled to 0° C on an ice bath and
NaBH4 (1.01g, .022 mol) was added portionwise over 1 hour. The mixture was allowed to warm
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to room temperature and then heated to reflux overnight. The mixture was concentrated under
reduced pressure then dissolved in H2O (50 mL) and extracted with CH2Cl2 (4  30 mL). The
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced
pressure. The oil was purified by column chromatography (SiO2, EtOAc/ hexanes 1:4) to give
46 as a thick yellow oil (957 mg, 43%). 1H NMR (400 MHz, CDCl3)  7.32-7.31 (m, 5H) 3.73 (s,
2H) 3.30 (s, 4H) 3.20 (s, 6H). NMR data is comparable to ref. 60.

O
N

OMe

1-Benzyl-3-methoxycarbethylidenylazetidine (62)
In a 50 mL round bottom flask were added the protected azetidine 46 (.741g, 3.58 mmol)
and 10 eq. 18 M H2SO4 (2 mL). The mixture was allowed to stir at room temperature for 3hours
then cooled to 0° C on an ice bath. The reaction was quenched with sat. NaOH (12 mL) and the
residue dissolved with H2O (30 mL) and CH2Cl2 (30 mL). The mixture was poured into a
separatory funnel and the layers separated. The aqueous layer was extracted with CH2Cl2 (4  20
mL) and the combined organic layers were dried over Na2SO4, filtered and concentrated under
reduce pressure. The N-benzylazetidinone 37 was immediately carried on to the next step. 1H
NMR (400 MHz, CDCl3)  7.35-7.34 (m, 5H) 4.08 (s, 4H) 3.88 (s, 2H).54
In a 100 mL round bottom flask were added LiCl (75 mg, 2.0 mmol), acetonitrile (25
mL) and a stir bar. Trimethylphosphonoacetate (0.22 mL, 2.0 mmol) was then added with
stirring. DBU (0.20 mL, 1.3 mmol) was added followed by the azetidinone 37. The mixture was
allowed to stir at room temperature overnight. The mixture was concentrated under reduced
pressure with minimal heat. The residue was partitioned over in H2O (20 mL) and CH2Cl2 (30
89

mL) and added to a separatory funnel. The layers were separated and the aqueous extracted with
CH2Cl2 (4  20 mL). The combined organic layers were dried over Na2SO4, filtered and
concentrated under reduced pressure. The oil was purified by column chromatography (SiO2,
EtOAc/ hexanes 1:3) to give 62 as a yellow oil (158 mg, 55% over two steps). 1H NMR (400
MHz, CDCl3/TMS)  7.33-7.26 (m, 5H) 5.68 (bs, 1H) 4.26-4.25 (d, J = 2.8 Hz, 2H) 4.01-4.00 (d,
J = 2.4 Hz, 2H) 3.78 (s, 2H) 3.68 (s, 3H).

13

C NMR (400 MHz, CDCl3/ TMS)  166.1, 157.9,

138.3, 128.6(4), 127.4, 111.9, 64.1, 63.2, 62.2, 51.1. Anal. Calc. for C13H15NO2•C2H2O4: C
58.63; H 5.58; N 4.56. Found: C 57.76; H 5.57; N 4.51. M.p 147-150° C.

O
N

OMe

1-Benzyl-3-methoxycarbethylazetidine (63)
In a 100 ml round bottom flask were added the azetidine 62 (610 mg, 2.81 mmol), 10%
Pd/C (65 mg) and dry THF (55 mL). The flask was evacuate of all gases and sealed under H2
gas (1 atm). The mixture was allowed to stir at room temperature overnight. The mixture was
then filtered through a pad of Celite, washed with EtOAc (50 mL) and concentrated under
reduced pressure to afford 63 as a yellow oil (611 mg, quantitative) without any further
purification. ). 1H NMR (400 MHz, CDCl3/TMS)  7.17-7.07 (m, 5H), 3.46 (bs, 5H), 3.36-3.32
(t, J = 7.2 Hz, 2H), 2.80-2.77 (t, J = 6.8 Hz, 2H), 2.69-2.66 (m, 1H), 2.45-2.43 (d, J = 7.6 Hz,
2H). 13C NMR (400 MHz, CDCl3/ TMS)  172.6, 137.8, 128.7(2), 128.5(2), 127.3, 63.3, 59.8,
51.5(2), 38.3, 27.2. Anal. Calc. for C13H17NO2•C2H2O4: C 58.25; H 6.19; N 4.53. Found: C
57.96; H 6.21; N 4.56. M.p 156-157° C.

90

N

O

General Procedure for 1-Benzyl-3-diphenylmethoxyethylidenylazetidine (29a, b and 30a, b)
To a 100 mL round bottom flask was added LiAlH4 (30 mg, 0.8 mmol) and dry THF (10
mL) then sealed under N2. The reaction was cooled to 0° C on an ice bath and the azetidine ester
62 (123 mg, 0.6 mmol) in THF (3 mL) was added slowly via syringe. The reaction was stirred at
0° C for 2 hours and quenched with a 10% solution of KOH (0.5 mL). The mixture was allowed
to come to room temperature with stirring for 1 hour and then poured into a separatory funnel.
The white solid in the flask was washed with CH2Cl2 (3  10 mL) and the washings added to the
separatory funnel. The organic layer was washed with phosphate buffer (30 mL) and the layers
separated. The aqueous layer was then extracted with CH2Cl2 (4  25 mL). The combined
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure with
minimal heat. The crude alcohol was immediately added to a 100 mL round bottom flask and
dissolved in benzene (70 mL). PTSA (750 mg, 4.0 mmol) and the corresponding benzhydrol
(1.85 g, 10 mmol) were added to the flask and fitted with a Dean-Stark trap. The reaction was
heated to reflux overnight.
The mixture was concentrated under reduced pressure and the residue was dissolved in
CH2Cl2 (20 mL). The organic phase was washed with saturated NaHCO4 (40 mL). The layers
were separated and the aqueous phase was extracted with CH2Cl2 (4  25 mL). The organics
were combined and dried over Na2SO4, filtered and concentrated under reduced pressure.
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N

1-Benzyl-3-diphenylmethoxyethylidenylazetidine (29a)
The oil was purified by column chromatography (SiO2, EtOAc) to give 29a as a yellow
oil (180 mg, 16% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.35-7.21 (m, 15H) 5.455.41 (m, 1H) 5.39 (s, 1H) 3.89-3.88 (d, J = 6.4 Hz, 4H) 3.82 (s, 2H) 3.71 (s, 2H).

13

C NMR (400

Mhz, CDCl3/ TMS)  142.4(2), 138.6, 136.8, 128.7(12), 127.7(2), 127.3, 117.3, 87.8, 65.7, 63.8,
62.4, 61.5. Anal. Calc. for C25H25NO•C2H2O4: C 72.79; H 6.11; N 3.14. Found: C 72.57; H
6.08; N 3.29. M.p 146.5-147° C.

F
O

N

F

1-Benzyl-3-(bis-4-fluorophenyl)methoxyethylidenylazetidine (29b)
The oil was purified by column chromatography (SiO2, EtOAc) to give 29b as a yellow
oil (80 mg, 16% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.36-7.26 (m, 10H), 7.047.00 (t, J = 8.4Hz, 4H), 5.45- 5.42 (m, 1H), 5.38 (s, 1H), 3.90-3.87 (t, J = 2.8Hz, 4H), 3.82 (s,
2H), 3.73 (s, 2H).

13

C NMR (400 MHz, CDCl3/ TMS)  163.7, 161.2, 138.6, 138.1, 138.0,

137.3, 128.9(4), 128.8(2), 128.7(4), 127.4, 116.9(2), 115.7, 115.5, 81.3, 65.7, 63.8, 62.4, 61.4.
Anal. Calc. for C25H25NO•C2H2O4: C 67.35; H 5.23; N 2.91.
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1-Benzyl-3-diphenylmethoxyethylazetidine (30a)
The oil was purified by column chromatography (SiO2, EtOAc) to give 30a as a yellow
oil (142 mg, 30% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.38-7.25 (m, 15H), 5.33
(s, 1H), 3.62 (s, 2H), 3.55-3.51 (t, J = 6.8Hz, 2H), 3.46-3.43 (t, J = 8.0Hz, 2H), 2.89-2.85 (t, J =
6.8Hz, 2H), 2.75-2.71 (m, 1H), 1.94-1.90 (q, J = 6.8, 6.4Hz, 2H).

13

C NMR (400 Mhz, CDCl3/

TMS)  142.7(2), 138.6, 128.8(4), 128.7(2), 128.6(4), 127.7(2), 127.2, 127.1(2), 84.0, 67.6, 64.3,
61.1(2), 34.9, 29.1. Anal. Calc. for C25H27NO•C2H2O4•0.25H2O: C 71.74; H 6.58; N 3.10.
Found: C 71.72; H 6.53; N 3.11. M.p 146.5-147.5° C.

F

N

O
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1-Benzyl-3-diphenylmethoxyethylazetidine (30b)
The oil was purified by column chromatography (SiO2, EtOAc) to give 30b as a yellow
oil (223 mg, 49% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.35-7.24 (m, 8H), 7.047.00 (m, 4H), 5.26 (s, 1H), 3.69 (s, 2H), 3.51-3.47 (t, j = 6.4 Hz, 2H), 3.40-3.37 (t, 6.0Hz, 2H),
2.85-2.82 (t, J = 7.6 Hz, 2H), 2.70-2.66 (m, 1H), 1.91-1.86 (q, J = 6.0, 7.2 Hz, 2H).

13

C NMR

(400 Mhz, CDCl3/ TMS)  163.6, 161.2, 138.3(3), 128.7(8), 127.2, 115.6(2), 115.4(2), 82.6,
67.6, 64.2, 60.9(2), 34.7, 29.1. Anal. Calc. for C25H27NO•C2H2O4: C 67.07; H 5.63; N 2.90.
Found: C 66.93; H 5.55; N 2.92. M.p 162.5-163° C

93

Dopamine Transporter Binding Assay. Binding of [3H]WIN 35,428 were done as described
previously.60,61 Male Sprague-Dawley rats (200-250 g, Taconic, Germantown, NY) were
decapitated and their brains removed to an ice-cooled dish for dissection of the caudate putamen.
The tissue was homogenized in 30 volumes ice-cold modified Krebs-HEPES buffer (15 mM
HEPES, 127 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.3 mM NaH2PO4, 10
mM D-glucose, pH adjusted to 7.4) using a Brinkman polytron and centrifuged at 20,000 x g for
10 min at 4°C. The resulting pellet was then washed two more times by resuspension in ice-cold
buffer and centrifugation at 20,000 x g for 10 min at 4°C. Fresh homogenates were used in all
experiments. Binding assays were conducted in modified Krebs-HEPES buffer on ice. The total
volume in each tube was 0.5 mL and the final concentration of membrane after all additions was
0.5% (w/v) corresponding to 200-300 mg of protein/sample. [3H]WIN 35,428 (2carbomethoxy-3(4-fluorophenyl)tropane 1,5-naphthalene disulfonate; specific activity 82.4
Ci/mmol, from New England Nuclear, Boston, MA) was added and the incubation was continued
for 1 hr on ice. The incubation was terminated by the addition of 3 mL of ice-cold buffer and
rapid filtration through Whatman GF/B glass fiber filter paper (presoaked in 0.1% BSA in water
to reduce non-specific binding) using a Brandel Cell Harvester (Gaithersburg, MD). The filters
were washed with three additional 3 mL washes and transferred to scintillation vials. Absolute
ethanol (0.5 mL) and Beckman Ready Value Scintillation Cocktail (2.75 mL) was added to the
vials, which was counted the next day at an efficiency of about 36%. For determination of Ki
values, triplicate samples of membrane suspension was preincubated for 5 min in the presence or
absence of the compound being tested. Each compound was tested with concentrations ranging
from 0.01 nM to 100 μM for competition against binding of [3H]WIN 35,428 (final
concentration 1.5 nM), in three independent experiments. Under these assay conditions, an
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average experiment yielded approximately 6,000 dpm total binding per sample and
approximately 250 dpm non-specific binding, defined as binding in the presence of 100 μM
cocaine. Each assay was replicated three times, and Ki values were determined using PRISM.
Serotonin transporter Binding Assay. Brains from male Sprague-Dawley rats weighing 200225 g were removed, the midbrain was dissected and rapidly frozen. Membranes were prepared
by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris (120 mM NaCl, 5 mM KCl; pH 7.4
at 25º C) using a Brinkman polytron (setting 6 for 20 sec) and centrifuged (20,000 x g) for 10
min at 4º C. The resulting pellet was resuspended in buffer and recentrifuged (20,000 x g for 10
min at 4º C). The final pellet was resuspended in cold buffer to a concentration of 15 mg/ mL
(original wet weight). Assays were conducted in the above Tris buffer at 25º C (room
temperature). The total volume of each tube was 0.5 mL and contained 1.4 nM [3H]citalopram
(specific activity 80 Ci/mmol; New England Nuclear, Boston MA) and 1.5 mg midbrain tissue
(original wet weight). [3H]Citalopram was added and the incubation continued for 60 min at
room temperature. Incubations were terminated by rapid filtration through Whatman GF/B
filters (presoaked in 0.3% polyethylenimine in water to reduce non-specific binding) using a
Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, MD). The filters were
washed twice with 5 mL cold buffer and transferred to scintillation vials. Beckman Ready Safe
(3.0 mL) was added and the vials were counted the next day using a Beckman 6000 liquid
scintillation counter (Beckman Coulter Instruments, Fullerton, CA) at an efficiency of 36%.
Nonspecific binding is determined using 10 μM fluoxetine (RBI, Natick, MA). Each compound
was tested at concentrations from 0.01 nM to 100 μM for competition against binding of
[3H]citalopram, in three independent experiments, each performed in triplicate. Each assay was
replicated three times, and Ki values will be determined using PRISM.
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Norepinephrine Transporter Binding Assay. Brains from male Sprague-Dawley rats
weighing 200-225 g were removed, the frontal cortex was rapidly dissected and frozen.
Membranes were prepared by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris (120
mM NaCl, 5 mM KCl; pH 7.4 at 25° C), using a Brinkman polytron (setting 6 for 20 sec) and
centrifuged (50,000 x g) for 10 min at 4°C. The resulting pellet was resuspended in buffer,
recentrifuged (50,000 x g) for 10 min at 4°C and resuspended in buffer to a concentration of 80
mg/mL. Assays were conducted in the above Tris buffer on ice. The total volume of each tube
was 0.5 mL and contained 0.5 nM [3H]nisoxetine (specific activity 80 Ci/mmol, New England
Nuclear, Boston, MA) and 8 mg frontal cortex tissue (original wet weight). Triplicate samples of
the membrane suspension were preincubated for 5 min in the presence or absence of the test
compound. [3H]Nisoxetine was added and the incubation continued for 1 hr on ice. Incubations
were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.05%
polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg,
MD). The filters were washed twice with 5 mL cold buffer and transferred to scintillation vials.
Beckman Ready Safe (3.0 mL) was added to the vials, which were counted using a Beckman
6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, CA) at an efficiency
of 36%. Nonspecific binding is defined as binding in the presence of 1 μM desipramine. Each
compound was tested at concentrations from 0.01 nM to 100 μM for competition against binding
of [3H]nisoxetine, in three independent experiments, each performed in triplicate. Each assay was
replicated three times, and Ki values were determined using PRISM.
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